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ABSTRACT
Aim
The aim of this study was to complete a pilot project to ascertain if the research
design was appropriate to determine whether a daily oral dose of probiotics can
reduce the rate of vaginal group B streptococcal (GBS) colonisation in pregnancy.
Methodology
A pilot randomised controlled trial was performed which recruited 34 GBS-positive
women who were approximately 36 weeks pregnant.

The participants were

randomly allocated to the control group, who continued with standard antenatal care,
or to the intervention group, which continued with standard antenatal care and
received a daily oral dose of probiotics for three weeks or until the birth of their
infant. A lower vaginal swab to detect the presence of GBS was collected three
weeks post consent or when a participant was in labour.
Results
No significant difference was found in vaginal GBS rates between the control and
intervention groups. Only seven of 21 women in the intervention group completed
the entire 21 days of probiotics. A subgroup analysis, including only those who had
completed 14 days or more of probiotics (n=16), also showed no significant
difference in vaginal GBS when compared to the control. As a secondary finding of
the analysis did show significantly more vaginal commensals in the probiotics group
(p=0.048).
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Discussion
There are five possible reasons for the lack of significant results:


The length of the intervention was too short.



The dosage of the probiotics was too low.



The wrong strains of probiotics were used.



The sample size was inadequate.



Oral probiotics are ineffective in impacting vaginal GBS.

Implications
The secondary finding of a significant increase of vaginal commensals (normal
vaginal flora, including Lactobacilli) in women who completed 14 days or more of
probiotics supports the potential of probiotics to impact GBS in pregnancy. The
presence of commensals should be included as an indicator in future research
projects. This pilot project has provided no evidence that probiotic use in later
pregnancy is unsafe.

Many possibilities remain for future research to further

investigate the use of probiotics to impact vaginal GBS.
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1. Introduction

1 INTRODUCTION
1.1 Background
Group B streptococcus (GBS) is a bacterium that colonises the vaginas of 15 to
25 per cent of pregnant Australian women (McIlwaine et al., 2006; Royal Australian
and New Zealand College of Obstetricians and Gynaecologists, 2012).

This

bacterium is the leading cause of infections in newborns in the developed world
(Centers for Disease Control and Prevention, 2010; Columbo et al., 2006; Ohlsson &
Shah, 2013). It can be passed from a woman to her newborn during the process of
labour and birth and has the potential to result in pneumonia, septicaemia and
meningitis in the infant (Centers for Disease Control and Prevention, 2010; Columbo
et al., 2006; Hassan et al., 2011; Jones et al., 2006; Matsubura et al., 2007; Ohlsson
& Shah, 2013; Valkenburg-van den Burg et al., 2006).
Presently across Australia, prenatal GBS screening and prophylaxis are widely
practised, though there is considerable variation in strategies between hospitals
(Angstetra et al., 2007; Connellan & Wallace, 2000; Hiller et al., 2005; May et al.,
2005). These strategies aim to identify women who are at risk of transmitting GBS to
their infants. These at-risk women are given intravenous antibiotics in labour to
inhibit the transmission (Royal Australian and New Zealand College of Obstetricians
and Gynaecologists, 2012; Reingold et al., 2007).

As a result of intrapartum

antibiotic prophylaxis, the incidence of early onset neonatal GBS disease in
Australasia fell from 1.43 per 1000 live births in 1993 to 0.25 per 1000 live births in
2001 (Daley & Isaacs, 2004). However, there are disadvantages associated with the
use of intravenous antibiotics.
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The disadvantages of giving intravenous antibiotics in labour include the
development of antibiotic resistance in GBS and other bacteria, and the disruption of
the early growth of good bacteria in the newborn’s gut (Baltimore, 2007; Centers for
Disease Control and Prevention, 2010; Cheng et al., 2006; Daley & Isaacs, 2004;
Edwards, 2006; Grimwood et al., 2002; Ohlsson & Shah, 2013; Pattern et al., 2006;
Rautava et al., 2012; Russel & Murch, 2006). In the United States and Canada, 20 to
35 per cent of labouring women now receive intravenous antibiotic prophylaxis
(Baltimore, 2007; Centers for Disease Control and Prevention, 2010; Chen et al.,
2005; Glasglow et al., 2005; Pattern et al., 2006).
It has been proven by many research studies that women with higher vaginal
colonisations of Lactobacillus are more likely to have no detectable vaginal GBS
colonisations (Altoparlak et al., 2004; Donders et al., 2000; Kubota et al., 2002;
Takeyoshi et al., 2002; Whitney et al., 2004). This finding generates the hypothesis:
could increasing Lactobacillus colonisation rates in pregnant women’s vaginas
decrease GBS colonisation rates?

One possible means of increasing the

Lactobacillus colonisation in women’s vaginas may be through the use of probiotics.

1.2 Aim
The aim of this study was to complete a pilot to ascertain if the research design was
appropriate to determine whether a daily oral dose of probiotics can reduce the rate
of vaginal group B streptococcal (GBS) colonisation in pregnant women.

1.3 Overview of thesis
The intent of this thesis is to give a succinct and understandable description of the
research that was performed into the impact of oral probiotics on vaginal GBS
colonisation rates and to provide a clear discussion of the implications of the
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completed study. The introductory chapter of this thesis provides background
information on the study being presented and an overview of what can be anticipated
in the following chapters.
The literature review in Chapter 2 describes the search strategies used to amass the
scientific information available pertaining to GBS, probiotics and vaginal health. As
probiotics are an emerging area of scientific interest, the published data on
previously completed research studies was limited. No previous clinical trials were
discovered that investigated the impact of probiotic use on GBS colonisation rates.
In reaction to this, the search field was broadened to include completed
investigations into the impact of probiotics on other vaginal health concerns, such as
bacterial vaginosis. The review also correlates the published information on the
impact of probiotic use by pregnant women, specifically addressing the area of the
safety of probiotic use in pregnancy.
Chapter 2 also identifies a gap in the available published scholarly information on the
impact of probiotics on GBS vaginal colonisation rates in pregnancy. It highlights
the need for well-designed, well-powered randomised controlled trials in the area of
probiotics and vaginal health.
The methodology and study design of the project are presented in Chapter 3. In this
chapter the theoretical framework of a pragmatic approach within a pilot randomised
controlled trial is described and justified. The chapter also describes and details the
methods used to conduct the research, including a description of the study site, study
population, recruitment strategies, sample size, intervention and observations. A
discussion of the data analysis methods utilised and the ethical considerations
pertaining to this study is also included in Chapter 3.
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The research findings are presented in Chapter 4. The SPSS computer program was
utilised as a tool in this chapter to assist with the analysis of the raw data. Two
significant findings emerged from the analysis, pertaining to the absence of adverse
events with the use of probiotics in later pregnancy and the positive potential for
further studies into the use of oral probiotics to impact vaginal GBS colonisation
rates. However, due to the small sample size, the potential for Type 1 errors is
increased.
In Chapter 5, the major findings are highlighted and discussed. The aim of this study
was to determine the appropriateness of the research design used in this pilot project.
The discussion chapter focuses on the implications of the results generated by this
study for future research designs. It also highlights the strengths of the study and the
information it has contributed to the growing body of knowledge regarding probiotic
use to impact the vaginal micro environment.
Finally, Chapter 6 concludes the thesis. In this chapter, the aim of the study and the
major findings are reiterated. The findings are then reflected upon in light of their
implications for future research projects and clinical practice.

4
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2 LITERATURE REVIEW
2.1 Introduction
This chapter reviews the current literature pertaining to group B streptococcal (GBS)
vaginal colonisation and probiotics in pregnancy. Due to the limited availability of
information on this topic evidence surrounding probiotics and bacterial vaginosis
(BV) in both pregnant and non-pregnant women is also included in this review.
A search was performed of the electronic data bases: Cochrane Library, Expanded
Academic, Health Reference Centre Academic, Health Sciences, Meditext, Medline,
Nursing and Allied Health Source, Popline, ProQuest, Sage, Science Direct, Springer
and Wiley Interscience. The search terms used were ‘probiotics’, pregnan*’,
‘urogenital’,

‘Group

B

Streptococc*’,

‘Lactobacillus’, as found in the abstract.

‘Streptococcus

Agalactiae’,

and

Additional journal articles were then

procured by identifying relevant studies in the body and reference lists of articles
found through the database search.
The inclusion criteria for the review were any articles pertaining to probiotics and
pregnancy, probiotics and GBS, or probiotics and BV. Studies were excluded if they
focused on urinary tract infections or in vitro experiments. Electronic auto alerts
were instigated throughout the duration of the study to allow for regular updates of
emerging literature in this area.
The bacterium GBS is the leading cause of infections in newborns in the developed
world (Centers for Disease Control and Prevention 2010; Columbo et al., 2006;
Hassan et al., 2011; Ohlsson & Shah, 2013). Fifteen to 25 per cent of pregnant
Australian women carry GBS in their vaginas (McIlwaine et al., 2006; Royal
Australian and New Zealand College of Obstetricians and Gynaecologists, 2012).
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The bacteria are passed from a woman to her newborn during the process of labour
and birth and may result in pneumonia, septicaemia and meningitis in the infant
(Centers for Disease Control and Prevention, 2010; Columbo et al., 2006; Jones et
al., 2006; Matsubura et al., 2007; Ohlsson & Shah, 2013; Valkenburg-van den Burg
et al., 2006). In Australia, approximately one per cent of maternal GBS carriers will
infect their infants at birth; of these infants, six per cent will die and many others will
sustain permanent neurological damage (Centers for Disease Control and Prevention,
2010; Connellan & Wallace, 2000).
As stated in the Introduction chapter, due to the severity of neonatal GBS infection, a
variety of strategies which aim to identify women at risk of transmitting GBS to their
infants are practised around Australia (Angstetra et al., 2007; Connellan & Wallace,
2000; Hiller et al., 2005; May et al., 2005). These at-risk women are given
intravenous antibiotics in labour to assist in inhibiting the transmission of GBS to the
neonate (Reingold et al., 2007; Royal Australian and New Zealand College of
Obstetricians and Gynaecologists, 2012).

However, there are disadvantages

associated with the use of intravenous antibiotics.
The disadvantages of giving intravenous antibiotics in labour include the
development of antibiotic resistance in GBS and other bacteria, and the disruption of
the early growth of good bacteria in the newborn’s gut (Baltimore, 2007; Centers for
Disease Control and Prevention, 2010; Cheng et al., 2006; Daley & Isaacs, 2004;
Edwards, 2006; Grimwood et al., 2002; Gronlund et al., 2011; Ohlsson & Shah,
2013; Pattern et al., 2006; Rautava et al., 2012; Russel & Murch, 2006).
Many studies are available which have shown that women with higher vaginal
colonisations of Lactobacillus are more likely to have no detectable vaginal GBS
6
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colonisations (Altoparlak et al., 2004; Donders et al., 2000; Kubota et al., 2002;
Takeyoshi et al., 2002; Whitney et al., 2004). These findings form the basis of this
study.

Can we impact the vaginal colonisation of GBS by manipulating the

Lactobacilli colonisation? One means of facilitating this manipulation process may
be through the use of probiotics.
This review of the literature has identified that there is a gap in the research on the
impact of probiotic usage on GBS vaginal colonisation in both pregnant and nonpregnant individuals. As a result, this review focuses mainly on related studies
investigating the impact of different probiotic strains on the incidence of bacterial
vaginosis, which, like GBS, is a bacterial infection of the vagina. The review also
summarises the available research surrounding the safety of probiotic use in
pregnancy.

Safety is an important issue which must be addressed prior to

undertaking research due to its obvious implications for future research, particularly
research into the impact of probiotics in pregnancy on GBS vaginal colonisation
rates. The next section defines the term ‘probiotic’ in order to assist in clarifying the
use of this word in the literature as opposed to the broader colloquial term used in
mainstream marketing.

2.2 Probiotics
Probiotics are defined as ‘live microorganisms which, when administered in adequate
amounts, confer a health benefit to the host’ (World Health Organisation, 2002).
Probiotics are readily available ‘over the counter’ in Australia. They are contained in
many dairy products, such as yoghurt, consumed daily by pregnant women.
Anecdotally, probiotics have been used by midwives for many years to manage GBS
in pregnancy, though no research studies have been performed to determine their
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effectiveness (Murry, 2002). Additionally, there are many websites extolling the
benefits of yoghurt with live cultures and probiotics for vaginal health.
Lactobacilli are one such probiotic microorganism. Lactobacilli are the primary
organisms in the vaginas of healthy women. Their colonisation of the vagina has
been shown to reduce the incidence of bacterial vaginosis, yeast vaginitis, urinary
tract infections and sexually transmitted diseases (Ehrstrom et al., 2010; Marcone et
al., 2010; Reid, 2008; Reid & Bocking, 2003; Zarate & Nader-Macias, 2006).
Similar to many urogenital infections, Lactobacilli colonise the vagina mainly
through ascension across the perineum from the rectum to the vagina (Reid &
Bocking, 2003; Lagenaur et al., 2011a).
In contrast to the advantages of naturally occurring Lactobacillus, many of the
current commercially available strains of probiotics raise concerns regarding their
efficiency in producing purported health benefits. The documented concerns relating
to this category of probiotics are that companies can make unsubstantiated claims,
the products can contain dead or unreliable probiotic contents, they can contain
inadequate numbers of probiotic strains, and they can have a poor shelf life (Reid,
2008; Reid et al., 2003; Senok, 2005). In order for an oral probiotic to be effective, it
must be able to survive passage through the gastro-intestinal tract. It must be able to
proliferate and colonise the digestive tract. It must be safe and effective, and it must
maintain its effect for the duration of the shelf life of the product (Barrons &
Tassone, 2008, Senok et al., 2005; Zarate et al., 2005).
In addition to these concerns, the effects of probiotics have been shown to be strain
specific; therefore, the use of an individual micro-organism strain is only justified in
procuring the specific benefits that it has been proven to convey (Martinez et al.,
8
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2009; Pham et al., 2008, World Health Organisation, 2002). For example, a specific
strain of Lactobacilli which has been proven to improve travellers’ diarrhoea cannot
also be assumed to improve eczema.

Each strain and its benefits need to be

determined individually. Another challenge surrounding probiotics is that in vitro
experiments do not necessarily translate to real-life health benefits in human and
animal models. As a result, it is necessary for individual specific strains to have been
proven in clinical trials in order to confirm their ability to produce specific health
outcomes in humans before beneficial claims can be made (Reid, 2008; World
Health Organisation, 2002).

2.3 Probiotics and bacterial vaginosis
There was no literature found specifically investigating the impact of probiotics on
the vaginal colonisation rate of GBS in either pregnant or non-pregnant women. One
area which has been investigated is the impact of probiotics on bacterial vaginosis.
Bacterial vaginosis (BV) is an overgrowth in the vagina of various anaerobic
bacterial species. It is associated with endometriosis, pelvic inflammatory disease,
complications of pregnancy and an increased risk of sexually transmitted diseases
(Reid et al., 2004; Wang et al., 2010). The studies discovered have shown promising
results regarding the impact of different strains of Lactobacilli on the incidence of
BV, both as a therapy in themselves and as an adjunct to antibiotic treatment. The
following section of this review presents the available research on probiotics and BV,
as classified by the specific probiotic strains presented in the literature.
2.3.1 Lactobacillus rhamnosus GR-1 and fermentum/reuteri RC-14
The combination of probiotic strains Lactobacillus rhamnosus GR-1 (GR-1) and
Lactobacillus fermentum/reuteri RC-14 (RC-14) has undergone much research with
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regard to BV.

Four trials have been completed that investigated the oral

effectiveness of GR-1/RC-14 to alter vaginal flora. One study by Reid et al. (2001)
involving 42 healthy female participants randomly assigned each woman to one of
four different treatment groups. There was no control in this study. Three groups
were given GR-1/RC-14 in different dosages. The fourth group was given a different
strain of probiotics, Lactobacillus rhamnosus GG. It was found that a daily oral dose
of more than 108 culture-forming units (cfu) of GR-1/RC-14 restored and maintained
healthy vaginal micro flora. No improvements were noted in the L. rhamnosus GG
group (Reid et al., 2001). Two other studies randomly allocated 64 (Reid et al., 2003)
and 59 (Reid et al., 2004) healthy women respectively to receive either a daily oral
dose of GR-1/RC-14 (>109 cfu) or a placebo for 60 days. Both studies showed
significant improvement in the vaginal micro flora in the intervention group, with
increased Lactobacilli colonisation and decreased yeast and coliform infections
compared to the control (Reid et al., 2003; Reid et al., 2004). A fourth study
(Anukam et al., 2006a) randomly allocated 40 participants diagnosed with BV either
to insert vaginally two gelatine capsules of GR-1/RC-14 (109 cfu) daily for five days
or to apply the antibiotic Metronidazole in vaginal cream twice daily for five days.
Post follow-up on days six, 15 and 30, this study showed BV was cured in
significantly more probiotic-treated participants compared with the antibiotic-treated
participants (Anukam et al., 2006a). These studies indicate that the Lactobacillus
strains RC-14 and GR-1 have the potential to impact vaginal health. The drawbacks
of each of these studies were the small sample sizes and the lack of reporting of
power calculations in each of the journal articles.
Two studies (Anukam et al., 2006b; Martinez et al., 2009) have also been undertaken
to demonstrate the effectiveness of GR-1/RC-14 (109 cfu) as an adjunct treatment to
10
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antibiotic therapy for BV. In the first study by Anukam et al. (2006b), which
involved 106 women diagnosed with BV, all the participants were given an oral dose
of the antibiotic Metronidazole twice daily for seven days.

The participants

randomised into the treatment group were then given oral GR-1/RC-14 twice daily
for 30 days and the control group was given a placebo twice daily for 30 days. After
30 days, 88 per cent of the treatment group no longer had BV. It was interesting to
note that in contrast, 40 per cent of the placebo group no longer had BV.
Similarly, a study by Martinez et al. (2009) involving 64 women diagnosed with BV
treated every participant with a single dose of Tinidazole. They were then randomly
assigned to the treatment or control group. The treatment group was given two oral
capsules of GR-1/RC-14 (109 cfu) daily for 28 days. The control group, on the other
hand, was given two placebo capsules daily for 28 days. On day 28, there was an
87.5 per cent cure rate for BV in the treatment group versus a 50 per cent cure rate in
the control group. These studies indicate that the use of these probiotic strains can
aid in the prevention of relapses of BV post antibiotic treatment. These results are in
addition to their potential as a treatment for BV independent of antibiotics.
2.3.2 Lactobacillus acidophilus
Another strain of lactobacillus that has been investigated with regard to BV is
Lactobacillus acidophilus.

One study (Hallen et al., 1991) randomly allocated

57 participants with BV to receive L. acidophilus (108 to 109 cfu) in vaginal
suppositories two times daily for six days, or a placebo. Follow-up immediately after
treatment found that 57 per cent of the probiotic group had normal findings while the
entire placebo group still had BV. No further follow-up was possible, as 22 of the
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participants who still had BV required treatment with antibiotics after the first
follow-up visit (Hallen et al., 1991).
A study by Drago et al. (2007) treated 40 BV-infected women with an L. acidophilus
douche (109 cfu/ml) for six days. There was no control group in this study. It found
that, post treatment, 30 of the participants had improved vaginal Lactobacilli counts,
while three participants remained unchanged and seven had decreased Lactobacilli
counts. Twenty to 23 days after the completion of treatment, it was found that the
increased Lactobacilli counts persisted in 29 of the participants. A third study also
claimed a clear increase in the colonisation of the rectum and vagina with
L. acidophilus and a significant reduction in the occurrence of BV after women
ingested culture-containing yoghurt for two months versus ingesting pasteurised
yoghurt for two months (Shalev et al., 1996). The validity of these claims needs to
be viewed with caution due to the extremely high attrition rate experienced in the
study. Another study (Delia et al., 2006), without a control group, administered
vaginal suppositories with L. acidophilus to 60 women with suspected or confirmed
BV. This study found vaginal Lactobacilli to be a successful treatment for BV.
Though these studies trend towards indicating that Lactobacillus acidophilus has the
potential to positively impact vaginal Lactobacilli colonisation, their lack of control
groups, high attrition rates and small sample sizes bring each of the individual
findings into question.
A final study (Ozkinay et al., 2005) involving L. acidophilus recruited 360 women
with vaginal infections. After receiving anti-infective treatment, the participants
were randomly allocated to receive either a vaginal tablet containing a minimum of
107 cfu of L. acidophilus and Oestriol daily for six days, or a placebo. This study
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found a significantly higher improvement in the vaginal ecology of participants in
the probiotics group versus the control group. This study adds to the argument of the
aforementioned research that Lactobacillus acidophilus is another strain of probiotics
with the potential to impact the micro flora of the vagina.
2.3.3 Other strains of Lactobacillus
In contrast to the positive findings of the studies mentioned, a study by Eriksson et
al. (2005) found no significant difference in outcome rates between its probiotic and
placebo groups. This study randomly assigned women with BV to the intervention
group or to the control group after a course of Clindamycin. The intervention group
used tampons impregnated with the Lactobacilli gasseri, casei and fermentum (106 to
108 cfu) during menstruation. The control group used a placebo. No significant
improvement was noted between the two groups. Another study (Larsson et al.,
2008) was performed which showed no significant difference in outcome rates
between the probiotics and placebo groups. In this study, women with BV were
randomly assigned, after a course of Clindamycin, to use vaginal capsules containing
Lactobacilli gasseri and rhamnosus (108 to 109 cfu) for 10 days or a placebo. Both
these studies highlight that clinical results are specific to individual probiotic strains.
This emphasises the importance of choosing the appropriate strains and dosages of
probiotics when trying to elicit a specific health benefit in the micro environment of
the vagina.
A final study (Ronnqvist et al., 2006) is of note because it is the only one to make
mention of GBS. In this study, 176 healthy, fertile women were randomly assigned
to wear vapour-permeable panty liners impregnated with Lactobacillus plantaron
(>5*108 per panty liner) 24 hours a day for four consecutive menstrual cycles or to
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use a placebo. This study found that, post treatment, Lactobacilli were found in the
labial samples of 86 per cent and in the vaginal samples of 54 per cent of women in
the probiotics group, but it did not show any significant decrease in the presence of
microbes. The study population had an extremely high prevalence of GBS among its
participants, with a 43 per cent GBS carrier rate. It reported that women with a high
number of Lactobacillus in their vaginas had a 17 per cent prevalence of GBS but the
use of panty liners impregnated with Lactobacillus plantaron did not lower the GBS
carrier rate. This is the only study that reported on the impact of such an intervention
on GBS. The results of this study highlight the need for further research to identify
whether a strain of Lactobacillus exists that would be effective in reducing GBS
colonisation rates in women, specifically in pregnancy.
The following section reports on the research conducted involving probiotic use in
pregnancy. It focuses mainly on the use of probiotics in pregnancy to impact BV and
the safety of probiotic use in pregnancy.

2.4 Probiotics in pregnancy
The clinical trials that have been completed investigating the impact of probiotics in
pregnancy have focused mainly on the use of oral probiotics to prevent the
development of atopic eczema in infants. No published studies were identified that
reported on the impact of probiotics on GBS vaginal colonisation rates in pregnancy.
In a related field, four studies (Krauss-Silva et al., 2011; Neri et al., 1993; Nishijima
et al., 2005; Thiagarajan, 1998) have investigated the impact of a daily dose of
probiotics, administered either orally or vaginally, on rates of bacterial vaginosis
specifically in pregnant women.
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One of these studies (Nishijima et al., 2005) randomly assigned 24 pregnant women
to receive either a daily dose of Lactobacillus jonsonii (109 cfu) or a placebo milk
drink for two weeks. The study discovered that the consumption of this probiotic
drink significantly increased the number of vaginal Lactobacilli and showed a trend
towards a decrease in BV pathogens. Another study (Thiagarajan, 1998) randomly
assigned 381 pregnant women with BV in their first trimester of pregnancy to receive
either an intravaginal dose of yoghurt twice daily for one week or an intravaginal
placebo. This study found that yoghurt was two-thirds as effective as antibiotics for
treating BV, as measured by the persistence or absence of BV indicators. A study by
Neri et al. (1993) randomly assigned 84 women with BV in their first trimester of
pregnancy to receive either yoghurt vaginal douching (L. acidophilus >108/ml) or
acetic acid tampons twice daily for seven days. This study showed an 87.5 per cent
clinical improvement rate at one and two months post treatment in the yoghurt group
versus a 37.5 per cent clinical improvement rate in the acetic acid group.
A final study by Krauss-Silva et al. (2011) randomised 644 women in their second
trimester of pregnancy to receive orally either two capsules of GR-1/RC-14 (109 cfu)
or a placebo for six to 12 weeks.
completed the study.

Sixty-two per cent of the women recruited

The aim of the study was to determine the impact of

administering oral probiotics to women in early pregnancy with asymptomatic BV on
premature delivery rates. Unfortunately, the trial was unable to be completed due to
resource restraints and had an insufficient study sample to estimate any statistically
significant effects. However, this study did not report any safety concerns with the
use of GR-1/RC-14 in its pregnant participants.
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These studies indicate the positive potential of probiotics to impact the vaginal micro
ecology in not only non-pregnant women but pregnant women as well. When
broaching the area of the therapeutic use of probiotics in pregnancy safety is an
obvious concern.

The following section addresses this concern, presenting the

available research pertaining to probiotic use and safety considerations in pregnancy.

2.5 Safety considerations
Are probiotics safe for the mother and the developing foetus when used in
pregnancy? Probiotics are strain dependent and their safety needs to be determined
on a strain by strain basis (Liong, 2008). Infections caused by Lactobacilli are
extremely rare in the general non-pregnant population. They have been implicated in
approximately 0.05 to 0.4 percent of combined cases of infective endocarditis and
bacteraemia. Most of these infections occurred in individuals with chronic diseases
or debilitating conditions such as recent surgery, organ transplant, valvulopathy,
diabetes mellitus, AIDS, acute pancreatitis and cancer (Barrons & Tassone, 2008;
Besselink et al., 2008; Boyle et al., 2006; Liong, 2008; Pham et al., 2008; World
Health Organisation, 2002). In light of this, it is necessary to monitor all strains for
potential adverse side-effects (Allen et al., 2010).
The studies mentioned earlier in this review, involving both healthy non-pregnant
and pregnant women, all reported mild, transient and rare adverse effects from
probiotic use. The most serious side-effect reported involved two cases of persistent
headache for the first three days of probiotic treatment in a sample of 106 nonpregnant participants (Anukam et al., 2006b).
When specifically considering the safety of probiotic use in pregnancy, there have
been other studies performed investigating probiotic use in pregnancy in relation to
16

2. Literature review

blood glucose control and the development of atopic eczema in infants. None of
these studies reported any adverse side effects in their total combined 984 pregnant
participants (Doege et al., 2012; Kalliomaki et al., 2001; Lahtinen et al., 2009; Leiten
et al., 2008; Luoto et al., 2010; Schultz et al., 2004; Wickens et al., 2008). One study
(Allen et al., 2010) traced adverse outcomes post-probiotic administration in
pregnancy until the infants were six months of age. In this study, pregnant women in
their last trimester of pregnancy were randomly allocated to receive Bifidobacterium
and Lactobacillus salivarius and paracasei (109 cfu) daily or to receive a placebo.
This study found that, of the 220 mother-infant dyads in the treatment group, the
reported adverse events did not differ significantly from the placebo group. (Allen et
al., 2010).
In order to further investigate the safety of probiotic use in pregnancy, Dugoua et al.
(2009) performed a meta-analysis of the available randomised controlled trials to
ascertain specifically the safety of Lactobacillus, Bifidobacterium and
Saccharomyces spp. during pregnancy. In total, eight studies met the inclusion
criteria. The meta-analysis indicated that administering certain strains of
Lactobacillus spp. and Bifidobacterium spp. did not have any effect on caesarean
section rate, birth weight, gestational age or birth malformations. There was not
enough evidence to determine the safety of Saccharomyces spp. in pregnancy.
In summary, the studies to date have shown no major adverse events in healthy nonpregnant and pregnant participants. It is imperative to stress that each strain is
specific in its health benefits and health concerns. Therefore, it is particularly
important to continue monitoring for the adverse effects of each specific strain of
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probiotics, particularly when involving vulnerable population groups such as
pregnant women.

2.6 Conclusion
In conclusion, this review has shown that there is adequate evidence in the literature
to indicate the potential for different probiotic strains to positively impact vaginal
ecology. Group B streptococcus is a bacterium that causes major health risks for
birthing infants when it colonises women’s vaginas in pregnancy. Through a review
of the literature, it is apparent that a gap in the evidence exists regarding the impact
of individual probiotic strains on the GBS vaginal colonisation rates of pregnant
women. The discovery of such a beneficial strain would contribute to the
development of strategies for the prevention GBS vaginal colonisation in pregnant
women, thereby reducing the need for intravenous antibiotics in labour while
ensuring the safety of birthing infants. In this quest to discover an appropriate strain
of probiotic to combat GBS, it remains important to recognise the potential for
adverse side-effects of probiotics and to be vigilant in monitoring for any safety
issues that may arise while investigating probiotic use in pregnancy.
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3 RESEARCH DESIGN
3.1 Introduction
As stated in the literature review chapter, research has consistently shown that
women with higher vaginal colonisations of Lactobacillus are more likely to have no
detectable vaginal GBS colonisations (Altoparlak et al., 2004; Donders et al., 2000;
Kubota et al., 2002; Takeyoshi et al., 2002; Whitney et al., 2004). One potential
means of manipulating Lactobacillus concentrations in order to attempt to impact the
GBS colonisation rates is through the use of probiotics. The aim of this study was to
complete a pilot project to ascertain whether the research design was appropriate to
determine if a daily oral dose of probiotics can reduce the rate of vaginal group B
streptococcal (GBS) colonisation in pregnancy.
The following chapter outlines and justifies the theoretical frameworks and the
research design used while conducting this research project. It also explains the
ethical issues surrounding the research methods and the intervention used.

3.2 Theoretical framework for the methodology
This section outlines and justifies the decision to utilise a pilot randomised controlled
trial (RCT) framework as the major method for this study. It also describes and
explains how a pragmatic approach was implemented within the RCT design in order
to increase the applicability and comprehensibility of the study results.
3.2.1 Quantitative methods
A pilot RCT was chosen as the research method for this study. The main aim of the
study was to ascertain whether the research design would be appropriate to explore
potential causal relationships between oral probiotic use and GBS vaginal
colonisation rates in pregnant women. The RCT has been identified as the research
19
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method which provides the highest level of evidence for determining the presence of
causal relationships and the effects of an intervention (Peat, 2001; Steen & Roberts,
2011). The features of an RCT include random allocation to control and intervention
groups, double blinding as possible and identical treatment for both groups except for
the intervention being tested (Hoffmann et al., 2013; Sibbald & Roland, 1998).
The key aspect of RCT is the randomisation process. This process serves to allocate
each participant to a group in an unbiased manner, thereby limiting the influences of
selection bias and known and unknown confounders (Hoffmann et al., 2013; Peat,
2001). In this study, once a participant had met the inclusion criteria and had
consented to involvement in the study, the participant was randomly allocated to
either the control or intervention group. Randomisation assisted in controlling for
any confounding factors that may have been present in the two different groups of
participants.
Another aspect to an RCT that assists in controlling for bias is the process of blinding
(Hoffmann et al., 2013; Sibbald & Roland, 1998). In this study, there was no
placebo; therefore, the researcher and the participants both knew the arm of the study
to which the participants belonged. However, the pathologists analysing the swabs
were blinded to each participant’s allocation in the trial. This ensured that there was
no bias in the formulation of the results of the vaginal swabs. The fact that the
pathologists analysing the swabs were unaware of the group allocation alleviates
concerns regarding bias in the study and contributes further confidence to the final
results generated.
Both the control and intervention groups continued to receive standard care in the
antenatal clinic throughout the duration of the study. The only difference that existed
between the care received was that the intervention group was given a daily oral dose
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of probiotics for three weeks. Since both groups were receiving comparable care,
any differences noted in the final analysis could be justifiably attributed to the
intervention.
Finally, a pilot study was undertaken for this project. Pilot studies are used to test
study appropriateness and feasibility (Peat, 2001). The decision to perform a pilot
study was influenced by the scope and resource limitations of the project. A pilot
study served to determine the appropriateness of the study design and of the
recruitment strategy prior to committing the time and resources to a large RCT.
3.2.2 Pragmatic study design
This study, in addition to the RCT model, embraced a pragmatic approach to
research. This approach is based on the fact that the ‘traditional criteria for scientific
validity do not in themselves guarantee usefulness to practitioners’ (Worren et al.,
2002, p. 1228). Even if results can be produced in a laboratory, these results do not
necessarily translate into knowledge that is applicable in real-life settings and useful
for improving clinical practice. A pragmatic approach is used to determine whether
an intervention will be successful when implemented under normal circumstances
(Steen & Roberts, 2011; Zwarenstein et al., 2008). Research with probiotics has
shown that results in vitro do not necessarily translate to intervention successes in
clinical trials (Reid, 2008; World Health Organisation, 2002). This emphasises the
importance of ensuring the effectiveness of probiotic interventions in real-life
clinical settings prior to declaring their health benefits.
The influences of a pragmatic approach can be identified in many details of the trial
design. The researcher did not collect the vaginal swabs for the study but the women
collected their own swabs, which is the standard means of GBS vaginal swabbing at
the research site.

To aid in achieving a level of standardisation in swabbing
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techniques, each woman received the same instructions on how to collect a lower
vaginal swab. Each participant collected both her own pre- and post-intervention
vaginal swabs, which ensured a degree of internal control in swabbing techniques.
Another design detail where a pragmatic approach was applied was in the pathology
technique used for determining the presence of GBS.

The standard pathology

methods for measuring GBS at the study site were used. One limitation of the
standard pathology tests is they do not give a quantified amount for the GBS colony
counts per vaginal swab. The results only specify the presence of a light, moderate
or heavy growth of GBS. These results are not sensitive enough to determine
whether a slight reduction in GBS colonisation has occurred due to probiotic use but
they would indicate whether GBS had been eradicated in a woman’s vagina. The
swabbing and pathology testing techniques used in this study replicated standard
procedures at the study site, making the results of this study immediately practically
applicable in the clinical setting.

3.3 Conducting the research
This pilot randomised controlled trial was performed from April 2011 to August
2011, with a follow-up telephone survey performed from November 2011 to March
2012. Funding for this project was assisted by a $2000 contribution from the New
South Wales Nurses and Midwives’ Association’s Edith Cavell Trust. The following
section describes the details of the recruitment and data collection processes to
conduct the research, including a description of the study site, study population,
recruitment strategies, sample size, intervention and observations.
3.3.1 Study site
The Sutherland Hospital was selected as the study site. The Sutherland Hospital is a
low-risk public birthing unit in the southern suburbs of Sydney, Australia. At this
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hospital all women attending the antenatal clinic routinely self-perform a lower
vaginal swab at 36 weeks gestation. If a woman’s swab result is GBS positive, she
then receives intravenous antibiotics in labour.

The vaginal GBS rate at the

Sutherland Hospital for 2008 was approximately 21 per cent (The Sutherland
Hospital Obstetrix database, retrieved June 2009).
3.3.2 Study population
The selected study population for this research was GBS-positive women attending
the antenatal clinic at the Sutherland Hospital. The GBS status of these women was
determined by the routine, self-collected lower vaginal swab performed at 36 weeks
gestation.
The following inclusion criteria were applied: age over 18 years, overall good health
and a normal, uncomplicated pregnancy. The exclusion criteria and their rationales
were as follows:


Diabetes: women with gestational diabetes have been shown to have an
increased risk of being GBS positive in pregnancy (Hakansson & Kallen,
2008).



A previous history of endocarditis/valvular heart disease: non-pregnant
individuals with these conditions have been shown to be at an increased risk
of developing sepsis with probiotic use (Boyle et al., 2006).



Any medical condition or those who were undergoing any treatment that
would cause their immune systems to be compromised: non-pregnant
individuals with these conditions have been shown to be at an increased risk
of developing sepsis with probiotic use (Boyle et al., 2006).

If a woman developed an infection at any time during the study, she was withdrawn
from participation but continued having data collected.
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In addition, women who had any language barrier that hindered their ability to read
and understand the provided information, which was in English, were excluded from
participation. Women with a language barrier were excluded from the study because
the resource limitations of the study did not make it possible to engage an interpreter
for such situations. As such, it would have been impossible to ensure consent was
informed, making it unethical to recruit such women.
3.3.3 Recruitment
Prior to commencing recruitment, it was important to inform the staff of the pending
research project. The obstetric team, antenatal and delivery suite midwives and
antenatal support staff were informed through on-site educational sessions and
through one-on-one conversations.

These sessions assisted in increasing the

awareness of the staff, which helped them to understand the role of the researcher
and to be able to answer questions from women in the antenatal clinic about the
research.
In order to inform pregnant women of this study, posters (Appendix A) were
displayed in the antenatal clinic at the Sutherland Hospital. When women attending
the antenatal clinic were approximately 33 weeks pregnant, they were given a
participant information sheet and a brochure describing the study and informing them
of a possible future invitation to participate in the study (Appendices B and F).
The recruitment process commenced once a woman who met the inclusion criteria
was determined to be GBS positive at 36 weeks. The woman then received a phone
call from the researcher with a formal invitation to participate. If a woman agreed to
be involved in the research, she was approached by the researcher the following
week at her antenatal appointment. At this time informed consent was obtained
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(Appendix E). The woman was then randomly assigned to receive both standard
care and a daily oral dose of probiotics for three weeks, or to continue with standard
care with the staff in the antenatal clinic. The randomisation process was computer
generated by an online site.

For the women who were assigned to be in the

intervention group, the probiotics were provided at the time of consent.
Women were recruited based on the results of their standard lower vaginal swab at
36 weeks gestation.

This decision capitalised on the results of this standard

procedure, avoiding additional expenses due to the resource limitations of the study.
3.3.4 Sample size and randomisation
A power calculation performed to determine the sample size necessary for a RCT
determined that a sample size of 217 participants per arm of the study would be
required to reach a 90 per cent significance rate. To perform the power calculation,
the vaginal GBS colonisation rate was assumed to be 21 per cent based on the
vaginal GBS rate at the study site in 2008 (The Sutherland Hospital Obstetrix
database, retrieved June 2009). The effect size used was determined G. Reid as
50 per cent (personal communication, 19 August 2009). The power calculation was
based on detecting the difference between two proportions using a normal
distribution approximation. Such a study was unrealistic due to scope and resource
limitations. A pilot project was utilised to assist in becoming the basis for future
power calculations and to determine the feasibility of the research design. This pilot
project chose to recruit as many women as possible within the three-month
recruitment time frame, with a minimum aim of 30 participants. A total of 34
women were recruited during this time period.
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Since the exact number of women who would be recruited was uncertain, a simple
randomisation method was applied using an online randomisation site to create a
table which randomised 100 potential participants (Kang et al., 2008). The numbers
on the table were covered until a woman gave informed consent to the researcher to
participate in the study. At this point the researcher revealed whether the woman
was assigned to the intervention or control group. The allocation ratio was intended
to be 1:1. Unfortunately, since only 34 women were recruited but 100 numbers had
been randomised, the allocation process was weighted heavily towards the
intervention group. As a result, the study ended up with 13 women in the control
group and 21 women in the intervention group. For a copy of the CONSORT flow
diagram, refer to Appendix H.
Neither the participants nor the researcher were blinded to the group allocation.
3.3.5 Intervention
The women who consented to be involved in the research were randomly allocated to
receive both standard care and a daily oral dose of probiotics Lactobacillus
rhamnosus GR-1 (GR-1) and Lactobacillus fermentum/reuteri RC-14 (RC-14) in a
dose of 108 viable strains for three weeks or to continue with standard care. The
probiotic strains GR-1 and RC-14 were chosen for use in this study because they are
the strains that have undergone the most clinical trials with respect to urogenital
health in women. They have been found to survive passage through the gastrointestinal tract and to colonise the vagina after oral administration (Gardiner et al.,
2002; Morelli et al., 2004). These strains have been shown to colonise the vagina
during the second week of oral administration (Morelli et al., 2004).
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justification of a three-week intervention period to impact Lactobacillus colonisation
of the vagina was based on this finding.
3.3.6 Observations
Three weeks post consent and post intervention, the GBS-positive women who were
recruited into the study self-collected a repeat lower vaginal swab. This swab was
given to the researcher or to the health practitioner at their appointment in the
antenatal clinic. These swabs were tested in the pathology department, which was
blinded to group allocation. If a participant commenced labour or spontaneously
ruptured her membranes prior to completion of the study, a second lower vaginal
swab was self-collected upon admission to the delivery suite and analysed by the
pathology department.
The researcher also collected demographic data about each woman at the time of
consent. These data were to assist in controlling for confounding factors. In order to
protect the privacy of the participants, all the data collected was de-identified at the
time of collection.

The medical record numbers of each participant were

documented with the data in order to allow for verification of any missing or
ambiguous information upon completion of the trial. The information collected about
each participant at the time of consent can be categorised into demographics and
pregnancy details. This information is as follows:
Demographics


ethnicity



age

Pregnancy details


body mass index (BMI)



number of pregnancies



number of children
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expected date of birth



number of weeks pregnant upon entry into the study



past history with GBS colonisation



the research group to which the woman was allocated.

At the end of the three-week intervention period, each woman was asked whether she
had taken any antibiotics during the trial. The women who received the probiotics
were also asked how often they had been able to take their daily dose of probiotics
and whether they had had any adverse reactions or side-effects during the trial.
After women in the trial had given birth, further information was collected. This
information can be categorised into maternal labour and birth details and neonatal
details. It is as follows:
Maternal labour and birth details


the development of pregnancy complications (which included the
development of infections)



the type of birth



the occurrence of antibiotic administration in labour



the final lower vaginal swab result

Neonatal details


the infant’s birth weight.

Please refer to the appendix for a diagram of the research design (Appendix C) and a
copy of the list of the additional data (Appendix D) that was collected about each
participant.
Six months post birth, a follow-up telephone survey of the participants was
performed. This survey was a requirement of the ethics board for ethics approval.
The intention of this survey was to aid in collecting further data on the safety of these
specific probiotic strains in pregnancy. The survey specifically addressed whether
the infant had any concerns at birth, which included neonatal GBS infection.

28

3. Research design

Appendix G lists the questions asked at the follow-up telephone survey. The postbirth questions were structured following the indicators used in two systematic
reviews conducted on the safety of probiotic use in pregnancy (Allen et al., 2010;
Dugoua et al., 2009).

3.4 Data analysis
The final vaginal swab results were not revealed until after each woman had given
birth. The results of this study, therefore, did not impact on the current management
of the women participating in the study. These GBS-positive women still received
intravenous antibiotics in labour, as was hospital policy. Once the data collection
phase was complete, all the raw data, including the final vaginal swab results, was
brought together and entered into the SPSS statistical computer program by the
researcher.

This process occurred in two stages: firstly, after the initial data

collection phase was complete and, secondly, after the six-month follow-up
telephone survey was complete.
statistical program.

The data were then analysed using the SPSS

This process was assisted by the statistical consulting

department of the University of Wollongong.
In order to test whether any differences existed between the intervention and control
groups, an independent t-test was applied to the continuous demographic data, such
as age and BMI. A t-test hypothesis states that the difference in the mean of a
variable when comparing two groups is equal to zero. The null hypothesis in a t-test
is that the difference in the means is NOT equal to zero. In this analysis it was
decided that if a t-test produced a significance level of greater than 0.05 then the null
hypothesis could be rejected, indicating that there was no difference between the
means of a variable when comparing the control and intervention groups. Therefore,
if the significance level was >0.05 it would indicate that, with regard to a specific
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demographic variable, both the probiotic group and standard care group were similar
(McDonald, 2009). In order to apply an independent t-test it was assumed that the
data were normally distributed. The small sample size made tests of normality, such
as the Shapiro-Wilk test, in the analysis unreliable. In order to confirm the use of the
independent t-test on the continuous data in these findings, the Mann-Whitney test
was applied to each continuous variable. The Mann-Whitney test is a non-parametric
test. All of the Mann-Whitney tests which were applied to the continuous variables
in the analysis had non-significant results, as did the independent t-test applied to the
same variables. The Mann-Whitney tests therefore verify the results of the t-tests in
this study (Batterham, personal communication, 2015; Newton & Rudestam, 2013).
To determine whether associations existed between the two groups, a Fisher’s exact
test was applied to the categorical data, such as the presence of vaginal GBS.
Normally a chi square test is used to test correlations but due to the small sample size
of this study the Fisher’s exact test was deemed more appropriate for this data set.
With this statistical test, the null hypothesis states that the two variables are
independent of each other and the alternative hypothesis states that they are NOT
independent. If the test applied to the data set produces a significance value of less
than 0.05 then the null hypothesis can be rejected and it can be assumed that a
relationship exists between the two variables (McDonald, 2009).

3.5 Ethics
Within a description of the methodology used, it is also important to discuss the
ethical considerations surrounding the study. This discussion justifies the research
methods from an ethical point of view, thereby ensuring that the study was
performed in a way that protected the integrity of the participants and their unborn
infants. The following section discusses the ethical issues pertaining to this study
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and its design. These issues have been categorised into safety considerations, risk of
coercion, informed consent and confidentiality.
Ethics approval for this study was granted by the University of Wollongong’s
Human Research Ethics Committee (HE 10/306). Site-specific approval was granted
through the South Eastern Sydney Local Health Network (SSA/11/STG/39).
3.5.1 Safety considerations
The primary ethical concern in this project surrounded the issue of safety
(Beauchamp & Childress, 2009). Could daily oral use of probiotics result in any
harm to the mother or the foetus? Probiotics comprise organisms that are identical to
those found in the human gastrointestinal tract and in the vagina. The available
research indicates that the risk to pregnant women of developing any infections as a
result of probiotic use is low and there is no expected risk to the developing foetus
(Kalliomaki et al., 2001; Lahtinen et al., 2009; Leiten et al., 2008; Liong, 2008;
Pham et al., 2008; Schultz et al., 2004; Wickens et al., 2008; World Health
Organisation, 2002). For a discussion of the issue of probiotic safety in pregnancy,
please refer to section 2.5, ‘Safety considerations’.
In order to maintain the safety of the participants, the exclusion criteria for this study
state that any woman with diabetes, a history of valvular heart disease/endocarditis or
any condition or treatment causing immune system compromise was unable to
participate in the study. These are all conditions that have been identified in the
literature as putting an individual at higher risk of developing infections with
probiotic use (Boyle et al., 2006). In addition, the research site was a low-risk
birthing unit. Therefore, women with major health concerns, including those
concerns that would put women at higher risk of developing an infection with
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probiotic use, would have their care transferred to a tertiary hospital. As a result, the
potential risk of harm to the study population was minimised.
Based on the above literature and the low-risk status of the birthing unit where the
study was performed, the anticipated risk to participants was minimal. In order to
further evaluate the safety of the probiotics used in the study, pregnancy details,
maternal labour and birth details, and neonatal details were collected from each
participant.

These details assisted to audit whether the intervention negatively

impacted on any of the participants.

A follow-up telephone survey was also

performed involving all the participants at six months post-partum in order to
generate further information on the safety of probiotic use in later pregnancy.
3.5.2 Risk of coercion
The researcher was a midwife employed in the antenatal clinic and delivery suite at
the study site. To reduce the risk of coercion, in the first three months of the study,
during the recruitment and initial data collection phases, the researcher did not work
in the antenatal clinic. This reduced the chance of the researcher being directly
involved with the care of potential participants. The result was that researcher did
not care for any participants during the antenatal stage of their pregnancy. After
these three months, the women naturally moved through their pregnancies and were
admitted to the delivery suite to give birth to their babies. There was a risk that the
researcher be involved in the care of participants when they were admitted to
delivery suite but by this stage in the research, the risk of coercion was minimal
because recruitment was already completed.
In addition to not being involved in the antenatal care of potential participants, the
initial contact of potential participants with the researcher was through a telephone
call. During this phone call, women who had been determined to be GBS positive
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were invited to participate in the study. The telephone call allowed a woman a
degree of anonymity if she decided to decline participation which would not be
present in a face-to-face encounter. If a woman declined to participate, she was not
approached again by the researcher to participate in the study.
It was also specified in the consent form and reiterated verbally at the time of consent
that women were able to withdraw participation consent at any time during the study
without ramifications for the care they received throughout their pregnancies. All
these factors combined to ensure the risk of coercion to potential participants was
minimised.
3.5.3 Informed consent
In this study, the participants were required to sign a consent form. All pregnant
women were given an information sheet when they were 33 weeks pregnant
(Appendices B and F).

GBS-positive women who indicated an interest in

participating in the study over the telephone were approached the following week in
the antenatal clinic by the researcher. At this time, informed consent was sought
(Appendix E). The delay between obtaining the information sheet, expressing an
interest in participation over the telephone and providing informed consent gave
women the opportunity to think about entry to the study and discuss it with their
partners prior to officially consenting.
The researcher’s direct involvement in the consenting process helped to facilitate
informed choice by allowing women the opportunity to ask any questions or to
clarify any issues prior to signing their consent. The information letter and the
consent form outlined all the foreseeable risks and benefits of the research and
contained the contact telephone numbers and email addresses of the researchers.
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This gave women the opportunity to contact the researchers if they had any questions
or concerns about the study. It also specified in the consent form that women were
able to withdraw their consent to participate at any time without ramifications to the
care they received throughout their pregnancies.
The information provided and the availability of the researchers for further questions
ensured that the participants were able to acquire all the information they required to
make an informed choice about involvement in the study.
3.5.4 Confidentiality
In order to protect the privacy of the participants, all the data collected was deidentified at the time of collection. The medical record numbers of each participant
were documented with the data in order to allow for verification of any missing or
ambiguous information upon completion of the trial. Once the study was completed,
all identifiable information, including medical record numbers, was deleted.
The researcher was the only staff member at the study site with access to the raw
data. For the duration of the data collection phase, the information was stored in a
locked cabinet at the research site. Once data collection was completed, the raw data
were transferred to a locked cabinet in the School of Nursing, Midwifery and
Indigenous Health at the University of Wollongong. The de-identified data were
entered in the SPSS database by the researcher to allow for data analysis. The data
were saved and stored on a password-protected laptop computer. The de-identified
state of the data has been preserved at any time when the data has been presented in
poster, written or oral format.
All of these actions have ensured the safeguarding of participants’ privacy with
respect to their involvement in the study.
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3.5.5 Ethics summary
As has been demonstrated above, all attempts were made to ensure the women and
the unborn infants participating in the study were protected physically,
psychologically and emotionally for the duration of the research. This can be seen
through the attention given not only to physical safety considerations but also to the
rights of women to make a free, uncoerced, informed choice and to have their
information remain private and confidential. In summary, the attention paid to all
these different aspects demonstrate that this study was performed in an ethical
manner.

3.6 Conclusion
In order to determine the appropriateness of this study design to address whether the
use of oral probiotics in pregnancy can impact vaginal GBS colonisation rates, a pilot
RCT was performed. This chapter has described the justification for the research
design used in this study.

It has achieved this, firstly, by describing the

methodological frameworks of a pilot RCT and a pragmatic trial, which were the
underlying foundations of the study. Secondly, it has detailed the design by
describing the study site, the study population, the recruitment strategy, the sample
size and randomisation process, the intervention, the observations and the data
analysis utilised in the study. Lastly, it explained the ethical concerns arising from
the study and the means by which the design addressed these concerns.
The following chapter describes the findings that were generated through the
research design detailed here.
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4 FINDINGS
4.1 Introduction
This chapter presents the statistical findings that were generated by the study. The
first group of findings has been organised into a comparison of the antenatal
demographics, a comparison of the final vaginal swab results and a comparison of
the final vaginal swab results of a subgroup of the participants. The second group of
the findings presents comparisons of the variables pertaining to safety considerations
within the study. These variables include antenatal, immediately postnatal and six
months postnatal safety considerations. These are presented in order to determine
the absence of adverse events associated with the intervention.
Between April 2011 and July 2011, 34 GBS-positive pregnant women experiencing
uncomplicated pregnancies were recruited into this study. All the participants were
in the late stages of their pregnancies at the time of recruitment. The average mean
gestation was 35 weeks and 5 days at the time when the first vaginal swab was
collected. A pregnancy is considered to be at term at 37 weeks.

Due to the

uncontrollable nature of labour and birth and the late stages of the participants’
pregnancies at the time of recruitment, a high attrition rate was anticipated. A threemonth recruitment phase was performed with an anticipated minimum of
30 participants. In total, 34 women were recruited to participate in the study during
this time frame.
Of these 34 participants, 21 women were randomly allocated to the intervention
group and 13 to the control group (for a complete explanation of the uneven
participant allocation, please refer to p 25-26). Of the 21 women in the intervention
group, seven women were able to complete the entire 21 days of daily oral
probiotics. This was mainly due to participants birthing prior to completion of the
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21-day intervention.

Seventeen women were successful in consuming at least

14 days of oral probiotics. Two participants did not collect their second lower
vaginal swab. This occurred due to the precipitous nature of their individual births.
Both of these women were allocated to the intervention group.
A research study conducted by Morelli et al. (2004) found that Lactobacilli colonised
the vagina after two weeks of a daily oral dose of GR-1 and RC-14 in a dose of
>108 culture-forming units. For the purpose of the data analysis, and based on this
research, the participants were further limited to a subgroup which included any
women who had completed 14 days or more of probiotics. This further reduced the
participants to 17 women in the intervention group and 13 women in the control
group. Of the 17 woman in the intervention group, one woman did not complete the
final lower vaginal swab due to the precipitous nature of her birth. This further
reduced the available final swab results in the subgroup to 16 in the intervention and
13 in the control groups.
A follow-up telephone survey of the participants was performed when their infants
were approximately six months old. The purpose of this survey was to collect further
data to ensure the absence of adverse events with the intervention. All 34 women
participated in this survey. No participants were lost to follow-up.
The following sections present the findings of this research project. It is important to
frame these findings within the context of its original design. This project was set
out to be a pilot. The aim was to ascertain the appropriateness of the design to guide
the development of future research projects. As such, the sample size was small and
lacks power. This increases the potential for Type 1 or 2 errors in the statistical
results (Borbasi & Jackson, 2008). Therefore, while the findings from this study are
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intended to guide future research, assertions made on the basis of these findings
alone should be considered carefully.
The small sample size made tests of normality for the continuous data in the analysis
unreliable.

In order to verify normal distribution and justify the use of the

independent t-test on the continuous data in this analysis, the Mann-Whitney test was
applied. All of the Mann-Whitney tests applied to the continuous variables in this
study had results which were non-significant, as were the results of the independent
t-tests when applied to the same variables.

The Mann-Whitney test is a non-

parametric test. The results of the Mann-Whitney tests support the results of the ttests in the findings (Batterham, personal communication 2015; Newton &
Rudestam, 2013).
The findings of the study have been classified into antenatal demographics, final
lower vaginal swab results, subgroup analysis of final lower vaginal swab results,
safety considerations and the six-month follow-up telephone survey.

4.2 Antenatal demographics
Upon entry to the study, antenatal demographic information was collected from each
participant.

This information included age, ethnicity, BMI, parity and previous

history of GBS. Null parity refers to a woman who is currently experiencing her first
pregnancy, which she has carried past the age of viability (Wong & Perry, 1998).
Due to the small sample size, information collected on ethnicity could not accurately
be statistically analysed.
In order to compare the demographic variables between the probiotic and standard
care groups, independent sample t-tests and Fisher’s exact tests were used. Using the
independent sample t-test, it was shown that the participants in the probiotics and
standard care groups did not differ significantly with respect to age (Probiotic:
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M=32, SD=4; Standard: M=30, SD=4.3, t(df)=1.7, p=0.1) and body mass index
(BMI) (Probiotic: M=23.4, SD=3.8; Standard: M=23.7, SD=4.3, t(df)=-0.2, p=0.8).
When a Fisher’s exact test was applied to the variables ‘Nulliparous’ and ‘Previous
history of GBS’, the results were also found to be non-significant (p=0.5 and 0.6
respectively, FET). This indicates that both the probiotics and standard care groups
in this specific group of participants have a degree of homogeneity with respect to
age, BMI, null parity and history of GBS. Therefore, these results aid to increase the
confidence that these factors, with potential confounding effects, should not
influence the findings of the study. Since the two groups are similar in these areas
prior to the intervention, it justifies the comparison of these two groups following the
intervention.

4.3 Final lower vaginal swab results
The aim of this study was to complete a pilot project to ascertain if the research
design was appropriate to determine whether a daily oral dose of probiotics can
reduce the rate of vaginal group B streptococcal (GBS) colonisation in pregnancy.
To determine whether a relationship existed in this study between oral probiotic
consumption and GBS-negative vaginal swab results, a Fisher’s exact test was
applied to the data.
4.3.1 Timing between the first and second vaginal swabs
In order to ensure consistency between the two groups and control for possible
confounding factors, the time between collecting the first vaginal swab and second
vaginal swab for the probiotic and standard care groups was compared. If one group
had a significantly longer time period between performing their first and second
vaginal swabs, this would have the potential to impact the number of swabs
spontaneously reverting to a negative result independent of the intervention. This
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comparison was performed using an independent sample t-test. In this analysis the
mean number of days between collection of the first and second vaginal swab for
both the probiotic and control groups was 25 days, producing a non-significant result
(Probiotic: SD=5.3; Standard: SD=9.7, t(df)=0.3; p=0.8). This indicates that the
number of days between collecting the two swabs was similar for both the probiotic
and standard care groups. In this analysis, it was assumed that the two participants
who missed collecting their second swabs due to precipitate labours, if it had been
possible, would have collected their swabs on the same day that they gave birth.
4.3.2 Comparison of final lower vaginal swab results
It has been verified that similarity exists between the intervention and control groups
in the aforementioned variables. Therefore, since it has been determined that a
degree of homogeneity exists between the probiotic and standard care groups in this
specific sample, the comparison of the final lower vaginal swab results between the
two groups is justified. In the control group, involving 13 women, it was found that
three women were GBS negative when the final swab was collected.

In the

probiotics group, involving 21 women, two of the participants had no final swab
collected. Of the remaining 19 women in the probiotics group, four were determined
to be GBS negative, as indicated by their final lower vaginal swab. Using the
Fisher’s exact test, it was discovered that the group of women consuming an oral
daily dose of probiotics did not have a significant decrease in GBS in their vaginas,
as indicated by their final swab result when compared with the control (p=0.7, FET).
A comparison of the final swab results has been summarised in Table 1 and Figure 1.
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Table 1: Comparison of final swab results by group allocation
Intervention status

Final Lower Vaginal Swab
Result (N)
Negative
Positive Total

Probiotics

4

15

21

Standard

3

10

13

Total

7

25

34

Figure 1: Comparison of final swab results by group allocation

4.4 Subgroup analysis of final vaginal swab results
4.4.1

Subgroup analysis of GBS results

The number of days that women in the intervention group took the probiotics varied
from six days to 21 days, with an average mean of 17 days. Only eight of these
participants completed 19 or more days, with the missing days being attributed to
forgotten doses. The reason why participants completed fewer than 19 days of
probiotics was that they birthed prior to completion of the course of probiotics. The
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foundation for the decision to perform a three-week intervention was the finding that
the probiotics RC-14/GR-1 in the dose of >108 culture-forming units can colonise the
vagina after 14 days of oral consumption (Morelli et al., 2004). The premise of the
current study was that women with higher colonisation of Lactobacilli in their
vaginas have a greater probability of being GBS negative. Therefore, if previous
research has shown that these probiotics can colonise the vagina after two weeks of
oral use, then, in the current study, it would not be expected for the women’s GBS
statuses to be impacted until at least 14 days of probiotic use. In light of this, a
further subgroup analysis of the final swab results was performed including only the
women in the intervention group who had completed at least 14 days of oral
probiotics.
The subgroup limited the intervention group to 17 women and the control group to
13 women. In the intervention subgroup, one woman did not have a final lower
vaginal swab collected due to precipitous labour, further reducing the intervention
group to 16 women. When the Fisher’s exact test was applied to this subgroup, the
results remained above significance (p=1.0, FET), indicating no difference in the rate
of GBS-negative final swabs between the intervention and control when including
only the women in the intervention who had completed at least 14 days of oral
probiotics. These results are summarised in Table 2 and Figure 2.
Table 2: Comparison of the subgroup analysis of final swab results from the
intervention and control groups
Intervention status

Final Lower Vaginal Swab
Result (N)
Negative
Positive Total

Probiotics

3

13

16

Standard

3

10

13

Total

6

23

29
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Figure 2: Comparison of subgroup analysis of final swab results by group
allocation

4.4.2 Subgroup analysis comparing the presence of commensals
A secondary, unexpected finding in this study was that the lower vaginal swab
results indicated the presence of commensals in a number of women’s vaginas. At
the study site, the pathology department routinely reported on both the presence of
GBS and the presence of commensals. Commensals are normal vaginal flora
(Barrons & Tassone, 2008; Lagenaur et al., 2011b; Rose et al., 2012). In this study,
the presence of commensals was reported in final vaginal swabs among the women
who took a daily dose of probiotics for at least 14 days: five women in the probiotics
group had commensals and no women in the standard care group had commensals.
Of these five women, none had had the presence of commensals reported in their
vaginas at the initial 36-week swab. When the Fisher’s exact test was applied to
determine the presence of an association between consuming oral probiotics and the
presence of commensals, a significant result was obtained (p=0.048, FET). This
result indicates that the women in this study consuming a daily oral dose of
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probiotics for 14 days or more had a significantly increased probability of having
commensals in their vaginas in comparison to the women allocated to the standard
care group. These findings have been summarised in Table 3 and Figure 3.
Table 3: Comparison of the presence of commensals by group allocation
Intervention status

Presence of Commensals (N)
No

Yes

Total

Probiotics

11

5

16

Standard

13

0

13

Total

24

5

29

Figure 3: Comparison of the presence of commensals by group allocation

4.5 Safety considerations
One of the major concerns surrounding probiotic use in pregnancy is the assurance of
safety for both the mother and the infant. A more detailed discussion of this topic
can be found in the literature review chapter. This section presents the findings of
the study pertinent to the safety of probiotic use in pregnancy. The safety indicators
for this section and for the questions in the six-month follow-up telephone survey
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have been adapted from two systematic reviews conducted on the safety of probiotic
use in pregnancy (Allen et al., 2010; Dugoua et al., 2009).

Furthermore, the

indicators for allergy-related concerns in the six-month follow-up telephone survey
were adapted from a systematic review of the impact of probiotic use in pregnancy
on eczema (Kalliomaki et al., 2001).
4.5.1 Antenatal concerns
Data were collected on each participant regarding the emergence of complications in
the pregnancy after entry to the study.

Two women were found to develop

complications, one with pregnancy-induced hypertension and one with pruritic
urticarial papules and plaques of pregnancy (PUPPS). Both of these women had
been allocated to the standard care group.
4.5.2 Side-effects
After the second vaginal swab was collected from each participant, information was
collected documenting the self-reported side-effects women in the intervention group
experienced from the probiotics. Two out of the 21 women in the probiotics group
stated having side-effects. One woman reported that she experienced an itchy throat.
She was uncertain whether this was due to the probiotics. One other woman reported
that the probiotics assisted her with her constipation.

None of the remaining

19 women reported any side-effects from the probiotic usage.
4.5.3 Birth outcomes
In order to further explore the area of probiotic safety in pregnancy, data pertaining
to a number of birth outcomes was collected. This included birth weight, gestation at
the time of birth, and mode of birth/delivery.
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4.5.4 Birth weight and gestation at the time of birth
The mean birth weight for the 21 infants born to the women in the intervention group
was 3,545 grams. The mean birth weight for the 13 infants born to women in the
standard care group was 3,542 grams. An independent sample t-test was applied to
the birth weights to determine if there was a significant difference between the two
groups with regard to birth weight. No significant difference was found (Probiotics:
SD=379; Standard: SD=370, t(df)=0.02, p=0.98).
The mean pregnancy gestation at the time of birth was also compared between the
two groups. This information was to aid in determining whether probiotics could
impact the time at which a woman may go into labour. It was calculated that the
mean gestation at the time of birth for the women in the probiotics group was
39.7 weeks and in the standard care group was 39.9 weeks. The results of the
independent sample t-test verified that there was no significant difference between
the two groups (Probiotics: SD=1.2; Standard: SD=1.0, t(df)=-0.7, p=0.5).
4.5.5 Mode of birth
The final safety indicator investigated with regard to birth outcomes in this study was
mode of birth.

The four identified modes of birth were normal vaginal birth,

instrumental birth, elective lower segment caesarean section (LSCS) or emergency
LSCS. An instrumental birth indicates the need for a vacuum or forceps delivery.
An elective LSCS refers to a caesarean section that has been planned in advance. An
emergency LSCS refers to a caesarean section that has been unplanned and has
occurred because of an unforeseen event, such as ‘foetal distress’ or ‘failure to
progress’.
Of the 21 women in the probiotics group, 19 experienced a normal vaginal birth, one
underwent an instrumental birth and one underwent an elective caesarean. Of the
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13 women in the standard care group, six women experienced a normal vaginal birth,
two underwent an instrumental birth, two underwent an elective caesarean and three
underwent an emergency caesarean. A summary of these findings can be found in
Table 4 and Figure 4.
Table 4: Summary of the modes of delivery for the intervention and control
groups
Intervention
status

Probiotics
Standard
Total

Mode of Delivery (N)
Vaginal
Birth
19

Instrumental
Birth
1

6
25

1

Emergency
LSCS
0

2

2

3

13

3

3

3

34

Figure 4: Mode of birth by group allocation
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Elective
LSCS

Total
21
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In order to compare these groups further, instrumental birth and emergency LSCS
were grouped together into assisted delivery. Elective LSCSs were not included in
this group, as they were planned in advance and were, therefore, births that did not
require an emergency intervention. This categorisation further reduced the data to
one woman in the probiotics group requiring an assisted delivery and five women in
the standard care group requiring an assisted delivery. When a Fisher’s exact test
was applied to this data, the women in the standard care group were shown to have
significantly more assisted deliveries than the women in the probiotics group
(p=0.02, FET). These results have been summarised in Table 5.
Table 5: Comparison of assisted delivery rates by group allocation
Intervention status

Assisted Delivery (N)
No

Yes

Total

Probiotics

20

1

21

Standard

8

5

13

28

6

34

Total

These findings imply that probiotics may have a protective property when consumed
in later pregnancy.

One possible confounding variable that may impact these

findings is the fact that women who are undergoing their first labour and birth
experience (nulliparous) have a greater probability of experiencing an assisted
delivery (Baskett et al., 2008). If there were more nulliparous women in the standard
care group as compared to the probiotics group, this could skew the data.

In

response to this, the data were further limited to the 18 nulliparous women
participating in the study. Within this category, one out of 10 nulliparous women in
the probiotics group underwent an assisted delivery and five out of eight nulliparous
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women in the standard care group underwent an assisted delivery. A Fisher’s exact
test indicated that the significance remained despite limiting the data to nulliparous
women (p=0.04, FET). A summary of the data can be found in Table 6. Due to the
small sample size, it would be unreasonable to conclude that probiotics have a
protective effect on birth outcomes, but these results do support the evidence that
probiotic use in later pregnancy does not produce negative birth outcomes.
Table 6: Comparison of assisted delivery rates in nullips by group allocation
Intervention status

Assisted Delivery (N)
No

Yes

Total

Probiotics

9

1

10

Standard

3

5

8

12

6

18

Total

4.5.6 Pre-labour spontaneous rupture of membranes
One unexpected outcome was the number of women who experienced a pre-labour
spontaneous rupture of membranes (SROM) in the study. Four out of the 21 women
in the probiotics group and one out of the 13 women in the standard care group had a
pre-labour SROM. When analysed further with a Fisher’s exact test, a comparison of
the SROM rates for the two groups was not statistically significant (p=0.6, FET).
However, this may be an area to be alert to for future studies. A summary of these
results can be found in Table 7.
Table 7: Comparison of pre-labour SROM rates by group allocation
Intervention status

Prelabour SROM
No

Probiotics

Yes
17

Total
4
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12

1

13

Total

29

5

34

4.6 Follow-up telephone survey
A follow-up telephone survey was performed approximately six months after birth
for all the women involved in the study. The participation rate for the telephone
survey was 100 per cent: all 34 participants were contacted and interviewed. The
purpose of the survey was to collect further data on the safety of probiotic use in later
pregnancy and to determine whether the probiotic use had had any impact on the
development of eczema, asthma or allergic rhinitis in the infants of the participants.
The survey collected some demographic information to aid in controlling for
confounding variables. This information included the method and duration of infant
feeding, the presence of smokers or pets in the home, the infant’s exposure to
childcare, and the family history of allergies, eczema and asthma. The survey then
collected information about the infant regarding the number of doctors’ visits,
presentations to the emergency department and hospitalisations. It also collected
information on whether the infant had had any concerns at birth, such as neonatal
GBS infection, and whether the infant had shown any signs of eczema, allergies,
asthma or allergic rhinitis. Finally, the mother was asked to rate the health of her
infant as ‘very healthy’, ‘occasionally unwell’ or ‘nearly always unwell’, and given
the opportunity to comment further on the health of her infant. Refer to Appendix G
to review a copy of the survey.
4.6.1 Demographic information
The demographic information collected by the survey was: method of infant feeding,
duration of exclusive breastfeeding, the presence of smokers in the house, the
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presence of pets in the house, the infant’s attendance at childcare, and the family
history of allergies, asthma or eczema. These are all variables that may contribute to
the overall health of the infant. These variables were compared statistically between
the probiotic and standard care groups of participants. An independent sample t-test
was applied to the variable length of exclusive breastfeeding (Probiotic: M=4.2
months, SD=2.2; Standard: M=3.5 months, SD=2.6, t(df)=0.9, p=0.4) and a Fisher’s
exact test was applied to the variables: presence of smokers (p=1.0, FET), presence
of pets (p=0.7, FET), attendance at childcare (p=1.0, FET) and family history (p=1.0,
FET). Based on these statistical analyses, no significant differences were found for
any of the variables.
The final demographic variable that was considered was the method of infant feeding
at six months of age. Of the 21 women in the probiotics group, 11 of their infants
were breastfed, nine infants were formula fed and one infant received a combination
of breast and formula feeds. Of the 13 women in the standard care group, seven of
their infants were breastfed, five infants were formula fed and one infant received a
combination of breast and formula feeds. A Fisher’s exact test cannot be applied to
an analysis with three variables. A chi square test was not appropriate due to the
small sample size. Therefore, no tests of significance were applied to this data. A
summary of these results can be found in Table 8.
Table 8: Comparison of infant feeding methods at six months between the
intervention and control groups
Intervention status

Method of Feeding at 6 Months (N)
Breast feeding

Formula

Combination

Total

Probiotics

11

9

1

21

Standard

7

5

1

13

18

14

2

34

Total
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4.6.2 Infant well-being at six months of age
The remaining sections of the survey collected data relating to the well-being of the
infant. The indicators used to ascertain this were: health concerns at birth, number of
visits to the doctor, number of visits to hospital emergency departments, number of
hospitalisations, use of medications, and presence of asthma, allergies, rhinitis or
eczema. The participants were also asked to rate their infants’ health as ‘very
healthy’, ‘occasionally unwell’ or ‘nearly always unwell’. Finally, the participants
were given the opportunity to comment further on health concerns relating to their
infants.
4.6.3 Concerns at birth
Among the participants, two women in the probiotics group and one woman in the
standard care group reported that their infants had concerns at birth.

The two

concerns noted in the probiotics group were low Apgar scores and clicky hips. The
one concern noted in the standard care group was transient tachypnoea of the
newborn. None of the participants reported neonatal GBS infections in their infants.
All of these concerns resolved after the immediate postpartum period. The Fisher’s
exact test indicated that there was no association between group allocation and
concerns at birth (p=1.0, FET).
4.6.4 Encounters with the medical system
The second group of indicators collected information on the number of encounters
the infant had had with the medical system in the first six months of life. These
encounters were broken down into visits to the doctor, visits to emergency
departments and hospitalisations. The routine vaccination visits to the GP were not
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included in the tally of doctors’ visits. The mean number of visits to the doctor for
the probiotics group was 1.5 visits. The mean number of visits to the doctor for the
standard care group was 1.9 visits. The maximum number of visits for one infant in
the probiotics group was 10 visits. These visits were for an infant with reflux who
had also contracted rubella in the first six months of life. The maximum number of
visits to the doctor in the standard care group was 12 visits. These visits were for an
infant who had developed a haemangioma post discharge from the hospital. He had
required fortnightly visits to a specialist at the Sydney Children’s Hospital. By six
months of age, these visits had been reduced to every second month.

An

independent sample t-test indicated no difference in means between the two groups
with respect to their number of doctors’ visits (Probiotics: SD=2.8; Standard:
SD=3.2; t(df)=-0.3, p=0.8).
The mean number of visits to the emergency department for the probiotics group was
0.2. The mean number of visits to the emergency department for the standard care
group was 0.2. The probiotics group had four presentations to emergency; the
standard care group had two presentations.

In the probiotic group, two of the

presentations were for the same infant who had begun projectile vomiting when
commenced on formula.

This infant was later diagnosed with cow’s milk

intolerance. One presentation was due to constipation when commenced on formula.
The final presentation was due to pyloric stenosis. This infant was hospitalised and
required surgery at Sydney Children’s Hospital.

The two presentations in the

standard care group were for a virus and bronchiolitis. The infant with bronchiolitis
was admitted and treated in hospital for the infection. An independent sample t-test
indicated that no significant difference existed between the mean number of
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presentations to the emergency department between the probiotics and standard care
group (Probiotics: SD=0.5; Standard=0.4, t(df)=0.2, p=0.8).
One infant in the probiotics group and two infants in the standard care group required
hospitalisation in their first six months of life. The infant in the probiotics group was
admitted to hospital for pyloric stenosis. The two infants in the standard care group
were admitted to hospital for bronchiolitis and haemangioma. A Fisher’s exact test
indicates that there was no association between incidence of hospitalisation and
group allocation (p=0.5, FET).
In this study, no significant association existed between the group allocation and
encounters with the medical system in the first six months of life. This further
supports the absence of adverse events in this study with the use of probiotics in later
pregnancy.
4.6.5 Medications
The incidence of infant medication use was also an indicator for infant well-being.
The most frequently reported medication taken by the infants in this study was
Losec. This is an anti-reflux medication. In the probiotics group three infants were
taking Losec and in the standard care group two infants were taking Losec. The only
other medication reportedly used was Propranolol, a beta blocker, which was being
used to treat one infant with haemangioma. A Fisher’s exact test statistic showed no
association between group allocation and incidence of medication use (p=0.7, FET).
4.6.6 Allergy-related health concerns
Information was also collected on the incidence of allergy-related health concerns
that had developed in the infants. The indicators used to determine these health
concerns were the occurrence of asthma, eczema, allergic rhinitis or allergies in the
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infants. Many research studies have indicated a trend in a reduction in allergyrelated illness in infants whose mothers used probiotics in later pregnancy
(Kalliomaki et al., 2001). This information aimed to discover whether any such
trend could be seen in this research project.
Only one woman reported having an infant with possible asthma. This woman was
in the probiotics group. Her infant had had some incidences of wheezing and was
currently under investigation with a paediatrician for asthma. One woman also
reported having an infant with rhinitis. This woman was in the probiotics group.
She described her infant as having a continuously runny nose. Both of her other
children and her husband were asthma sufferers and they also had other allergyrelated health concerns. Only one woman also reported having a child with allergies.
This woman was in the probiotics group. Her infant had been diagnosed with cow’s
milk intolerance after commencing on formula. These frequencies were too low to
permit reliable statistical analysis.
The final allergy-related concern that was explored was the incidence of eczema.
Three women reported that their infants experienced mild skin rashes or irritations
but were uncertain whether this was eczema. Two of these women were in the
probiotics group and one woman was in the standard care group. One woman in the
probiotics group and three women in the standard care group reported eczema in
their infants. Of this total of seven women, all but one quantified their infant’s skin
concerns as mild or slight. When all the uncertain answers were assumed to be yes
and the Fisher’s exact test was applied to this variable, no significant association was
shown to exist between incidence of eczema and group allocation (p=0.4, FET). For
a summary of these findings, see Table 9.
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Table 9: Summary of incidence of eczema by group allocation
Intervention status

Incidence of Eczema (N)
No

Yes

Total

Probiotics

18

3

21

Standard

9

4

13

27

7

34

Total

4.6.7 Overall health
The final indicator used to assist in determining the overall well-being of the infants
of the study participants at six months of age was a scale which asked women to
describe their baby’s health as: ‘very healthy’, ‘occasionally unwell’ or ‘nearly
always unwell’. Only one woman described her infant as ‘occasionally unwell’; all
the other participants described their infants as ‘very healthy’. This woman was in
the standard care group. Her infant had been diagnosed with haemangioma at three
weeks of age and at six months required twice daily medication and frequent followup with doctors. These results were too low to permit for reliable statistical analysis.
As a conclusion to the telephone survey, women were asked whether there were any
other health concerns that they would like to mention regarding their baby. Three
participants offered further responses to this question. One woman in the probiotics
group reported that her infant was seeing a physiotherapist once a month because the
infant preferred to turn her head to one side. Another woman in the probiotics group
reported that her infant had had one episode of diarrhoea in the past six months.
Finally, one woman from the standard care group reported that her infant was a poor
sleeper.
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4.6.8 Conclusion to six-month follow-up telephone survey
The study lost no participants to follow-up. All 34 participants were contactable for
the six-month follow-up telephone survey. The data provided by the six-month
follow-up study found that no significant differences existed between the
confounding variables in the probiotics and the standard care groups. The study also
found no differences between the two groups relating to the overall health of the
infants of the study participants at six months of age. These findings further support
the lack of adverse events with probiotic use in later pregnancy in healthy women
experiencing uncomplicated pregnancies.

4.7 Conclusion
In summary, this study found that no differences existed between the probiotics and
standard care groups with regard to demographic information collected both at the
time of recruitment and at the time of the six-month follow-up survey.
Further, no significant difference was found between the two groups with regard to
most of the safety indicators investigated in the study. The only difference that was
discovered was in mode of delivery, where women in the standard care group were
found to have a greater incidence of assisted deliveries. This difference remained
even when the data were limited to nulliparous participants. These findings further
support the lack of adverse events with probiotic use in later pregnancy in healthy
women experiencing uncomplicated pregnancies.
The aim of this study was to ascertain the appropriateness of the research design to
determine whether a daily oral dose of probiotics could impact a pregnant woman’s
GBS status, as indicated by a lower vaginal swab. The women in the probiotics
group did not show a reduction in the incidence of GBS in their vaginas in
comparison to the standard care group. A subgroup analysis, including only women
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in the intervention group who had taken at least 14 days of probiotics, also found no
reduction in the incidence of vaginal GBS in comparison to the standard care group.
But an unexpected, secondary finding did show that the subgroup had a significant
increase in the presence of commensals in the vaginas of the women in the probiotics
group. This finding has ramifications for future studies, as will be explored further
in the discussions chapter.
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5 DISCUSSION
5.1 Introduction
The following chapter discusses the multiple findings that have been generated by
this research project.

The hypothesis of the study asked the question: if

Lactobacillus colonisation rates can be increased in pregnant women’s vaginas,
could this result in a decrease in group B streptococcal (GBS) colonisation rates?
One potential means of manipulating Lactobacillus concentrations in order to
attempt to impact GBS colonisation rates is through the use of probiotics. The aim
of this study was to complete a pilot project to ascertain if the research design of this
study was appropriate to determine if a daily oral dose of probiotics can reduce the
rate of vaginal group B streptococcal (GBS) colonisation in pregnancy.
This research project did not discover any significant difference in vaginal GBS
colonisation rates in women who had consumed daily oral doses of probiotics as
compared to women who had not. This chapter discusses the possible explanations
for the lack of positive results in this study. It also presents the limitations of the
study.

Finally, it presents the strengths of the study with an emphasis on the

information that has been generated to aid in the development of future research
designs.

5.2 Possible reasons for the lack of results relating to probiotic use and
vaginal GBS
The aim of this study was to complete a pilot project to ascertain if the research
design was appropriate to determine whether a daily oral dose of probiotics can
reduce the rate of vaginal group B streptococcal (GBS) colonisation in pregnancy. In
this study, only seven of the 21 participants in the intervention group succeeded in
completing the full 21 days of probiotics. In order to manage this problem, a
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subgroup analysis was performed including participants in the intervention group
who had completed 14 days or more of probiotics. This decision was based on
research which has shown that Lactobacilli rhamnosus GR-1 (GR-1) and
fermentum/reuteri RC-14 (RC-14) can colonise the vagina after 14 days of oral
consumption (Morelli et al., 2004; Reid et al., 2001). The subgroup analysis found
no significant difference in the rate of vaginal GBS post intervention between the
control and probiotic groups.
As this was a pilot study, one of the purposes of the study was to analyse the results
in the light of the study design in order determine areas that require improvement for
future designs. There are numerous potential explanations for the lack of positive
findings in this study. These explanations include: inadequate length of intervention,
incorrect strain of probiotic, inadequate dosage of probiotic, and possible ineffective
treatment. The following sections address the possible explanations for the lack of
positive results in further detail, with the intention of aiding the design of future
research projects.
5.2.1 Inadequate length of intervention
The initial expected length of the intervention period was three weeks of probiotic
consumption. As stated earlier, due to the late gestation of 36 weeks at which the
participants were recruited and due to the unexpected nature of labour and birth, only
seven of the 21 participants allocated to the intervention group were successful in
completing the entire three-week intervention. In response, a subgroup analysis was
completed including the participants in the intervention group who had completed
14 or more days of probiotics. A subgroup analysis examines the effects of the study
on different subgroups within the study after analysing the main hypothesis of the
study (Peat, 2001). This limited the participants in the intervention group to 17. One
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of these participants was unable to collect a final vaginal swab due to the precipitous
nature of her labour. This further limited the subgroup analysis to 16 participants in
the intervention group.
The late gestation at recruitment—and the resulting large number of participants
unable to complete the intervention—is an obvious shortfall of the study design. It
was decided to recruit women in the final weeks of their pregnancies in order to
utilise the vaginal GBS screening that was already being routinely performed at the
study site at 36 weeks gestation.

This choice was purely one of economic

rationalisation. This study has made it obvious that this gestation was too late to
commence the intervention.
Previous research which procured positive results with respect to bacterial vaginosis
with the use of the same probiotic strains as the current study had an intervention
period of between 28 and 60 days (Krauss-Silva et al., 2011; Reid et al., 2003; Reid
et al., 2004; Anukam et al., 2006b; Martinez et al., 2009). This further emphasises
that future research will need to intervene at an earlier gestation and aim for at least a
four-week intervention period.
In addition, a secondary, unexpected finding of the study was that women who had
taken daily probiotics for at least 14 days were found to have significantly more
commensals in their vaginas in the probiotics group versus the control group.
Commensals are normal vaginal flora, such as Lactobacilli (Barrons & Tassone,
2008; Lagenaur et al., 2011b; Rose et al., 2012). This finding suggests that possibly
the probiotics had begun colonising the vaginas of the women in the intervention
group with Lactobacilli but the colonisation was not significant enough to impact on
the colonisation of GBS. As such, this finding sways the reason for the lack of
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positive results towards a problem with the length of the intervention, with the
dosage of the intervention or with both.
5.2.2 Inadequate probiotic dosage
Another possible explanation why the probiotics did not impact on the vaginal GBS
colonisation rates of the participants in this study is that the probiotic dosage may
have been too low. The women randomly assigned to the intervention group
consumed a daily oral dose of the probiotics Lactobacillus rhamnosus GR-1 (GR-1)
and Lactobacillus fermentum/reuteri RC-14 (RC-14) in a dose of 109 viable strains.
Reid et al. (2003, 2004) report that this dosage positively impacted the vaginal micro
flora of their participants when given daily for 60 days. Alternatively, Anukam et al.
(2006b) and Martinez et al. (2009) both found GR-1 and RC-14 to positively impact
the cure rate for bacterial vaginosis post-antibiotic treatment when given in a dosage
of 109 viable strains twice daily for 30 days in its non-pregnant participants. These
research projects would support the consideration of a twice daily dose, instead of a
once daily dose, of probiotics if using a 30-day intervention period for future studies.
The one challenge that may arise from increasing the probiotic dosage from once
daily to twice daily in future studies would hedge around safety issues. In order for
ethics approval to be obtained, it would be necessary to adequately prove to the
ethics board that this increased dosage would not cause harm to the pregnant woman
or her unborn child. The ethics process for this study took one year due to the
justifiably weighty concern placed on the safety of women and their unborn infants
by the ethics board when exploring emerging treatments in pregnancy.

One

stipulation placed on this study by the ethics board prior to approval was that a
follow-up survey be completed six months after each participant’s birth in order to
further explore the issue of safety. Based on this experience, it can be anticipated
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that an increase in dosage would also come under high levels of scrutiny by the
ethics board.
5.2.3 Incorrect strain of probiotic
Another potential explanation for the lack of a significant change in vaginal
colonisation rates in the participants who consumed daily oral probiotics is the
possibility the study used the incorrect strain of probiotics (Lamont et al., 2011). The
probiotic strains Lactobacillus rhamnosus GR-1 and reuteri/fermentum RC-14 were
chosen because they have been shown to survive passage through the gastrointestinal tract and to colonise the vagina after oral consumption (Morelli et al., 2004;
Reid et al., 2001; Reid et al., 2003; Reid et al., 2004). This feature of these strains
made them a justifiable choice for use in this study.
Recently, two separate studies have emerged which have performed in vitro
experiments specifically investigating the impact of different strains of Lactobacillus
on GBS (Bodaszewska-Lubas et al., 2012; Ruiz et al., 2012). The study by Ruiz et
al. (2012) found that the Lactobacillus strains rhamnosus L60 and fermentum/reuteri
L23 have probiotic potential for the control of vaginal GBS colonisation. The strains
used by Ruiz et al. (2012) and the strains used in the present study are similar to the
species level. The strains used in the present study are currently manufactured and
readily available within the Australian market. All these factors continue to support
the use of RC-14 and GR-1 in future studies.
On the other hand, probiotics have been shown to have strain-specific health benefits
(Martinez et al., 2009; Pham et al., 2008; World Health Organisation , 2002). This
makes room for the possibility that the probiotic strains used in this study, though
they colonise the vagina, may not have the ability to impact on GBS colonisation.
The second in vitro study by Bodaszewska-Lubas et al. (2012) found Lactobacillus
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plantarum C11 to have the strongest antibacterial properties against GBS. In
addition, Lamont et al. (2011), in their review on impacting genital tract flora using
molecular based techniques, recommend that ‘future research should concentrate on
the Lactobacilli that are prevalent in the vagina, rather than on species such as L.
fermentum and L. rhamnosus’ (p. 538). These authors recommend focusing on the
Lactobacillus strains L. crispatus, L. iners, L. jensenii and L. gasseri when
conducting research to impact vaginal health. The use of L. jensenii can further be
supported by research done using monkeys (Lagenaur et al., 2011a&b).
Since this is an emerging area of research, many new studies are being published
each year investigating the impact of probiotics on the vaginal ecology of women.
These studies are being completed using a variety of strains of Lactobacilli and using
both oral and vaginal administration.

Studies continues to support the positive

potential of probiotics to modulate the vaginal microbiota. It will be interesting to
discover which strain or combination of strains emerge as the best choice for vaginal
health through future research (Ehrstrom et al., 2010; Marcone et al., 2010;
Stojanovic et al., 2012; Vitali et al., 2012; Wang et al., 2010).
In summary, if an increase in length of intervention time and an increase in probiotic
dosage did not improve the results of this study, it would be justifiable to explore the
impact of other strains of probiotics on vaginal GBS colonisation prior to rejecting
the hypothesis.
5.2.4 Ineffective treatment
The final possibility for the lack of significant results pertaining to the use of oral
probiotics to impact vaginal GBS colonisation rates is that probiotics may be an
ineffective treatment. Before arriving at this final conclusion, the other possible
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explanations that have arisen from the study design need to be explored further with
future research projects.
5.2.5 Conclusion to possible reasons for the lack of positive results
There is a very real possibility that the strains chosen for this study may not be the
most effective probiotics for impacting vaginal GBS or that this may be an
ineffective treatment for the control of vaginal GBS. However, the research, at this
stage, indicates that the most logical explanations for the lack of positive results are
the length of intervention and the dosage. Once these areas have been further
investigated and no impact noted, a change of probiotic would then be justified.
After all these avenues have been explored, it would be prudent to reject oral
probiotics as a possible treatment for vaginal GBS.

5.3 Limitations to the study design
As stated earlier, this was a pilot project. It was intended to be the preliminary
testing to determine the viability of the study design’s ability to address the study
hypothesis. The proposed hypothesis was that probiotics will decrease vaginal GBS
colonisation rates in pregnant women. The fact that this study was a pilot project and
that it was based on a pragmatic approach to research generates limitations regarding
the results. This section expands on these limitations.
5.3.1 Sample size
One of the limitations present in this study was the small sample size. In total,
34 women were recruited over a three-month period. Initially, a power calculation
was performed to determine the sample size necessary for a large randomised
controlled trial (RCT). It was calculated that a sample size of 217 participants per
arm of the study would be required to reach a 90 per cent significance rate. A pilot
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study, with a small sample size, was utilised to determine the feasibility of the study
design and of the recruitment strategy prior to committing the time and resources to a
large RCT.
The small sample size in the study gives rise to the increased risk for Type 1 or 2
errors in the statistical results. A Type 1 error is when a true hypothesis is rejected
and a Type 2 error is when a false hypothesis is accepted (Peat, 2001). Therefore,
despite the small sample size, the findings of this study can serve to guide future
research. The small sample size limits the generalisability of the results. It also
means that the magnitude of the results needs to be cautiously interpreted in the
context of their original purpose. This purpose was to serve as a guide for future
study designs.
5.3.2 Uneven distribution of random allocation to control and intervention
groups
Another complication that the small sample size contributed towards was the uneven
distribution of the random allocation to the control and the intervention groups. A
three-month data collection time frame was set, with an anticipated minimum
number of 30 participants and an uncapped maximum number of participants to be
recruited within this time frame. A simple randomisation strategy was utilised in the
study (Kang et al., 2008). The randomisation process was computer generated by an
online site. One hundred possible participants were randomised into group 1 or
group 2. The participants allocated to group 2, the intervention group, were heavily
weighted at the beginning of the randomised series. Therefore, of the 34 women
recruited, 21 were randomised to the intervention group and only 13 to the control
group. Though unplanned, this uneven distribution worked in well with the research
because, when the results were limited to only the participants in the intervention
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group who had completed 14 or more days of probiotics and who had completed the
final vaginal swab, only 16 participants remained. The subgroup analysis, therefore,
ended up with 13 women in the control group and 16 women in the intervention
group.
In addition, despite the uneven distribution, when the two groups were statistically
compared they were found to be similar in their antenatal demographics, length of
time between first and second vaginal swabs, and gestation at birth. Since the two
groups were comparable in these areas, this minimised the concern about external
confounding factors that may have impacted the final vaginal swab results (Peat,
2001). The comparison of the final vaginal swab results was therefore justified.
Even though the uneven distribution did not appear to adversely impact the study, it
did not produce ideal circumstances for data analysis.

Simple randomisation

strategies have been noted to be problematic in trials with small sample sizes, as they
can produce unequal numbers of participants between groups.

A block

randomisation technique would have been more appropriate to control for equal
distribution of participants between groups in this study (Kang et al., 2008).
Alternatively, a larger sample size of greater than 100 participants would have
eradicated the limitation produced by a simple randomisation method.
5.3.3 Timing of intervention
As discussed in detail in section 5.2.1, ‘Inadequate length of intervention’, the timing
of the intervention was a glaringly obvious limitation of the study. The late gestation
at which the participants were recruited and at which the intervention was
commenced resulted in only seven of the 21 participants in the intervention group
completing the entire 21 days of probiotics. This accounts for a 66 per cent attrition
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rate. For future research studies, it is imperative that the recruitment and intervention
commence much earlier in the third trimester of pregnancy.
5.3.4 Pragmatic design
A pragmatic approach is based on the fact that the ‘traditional criteria for scientific
validity do not in themselves guarantee usefulness to practitioners’ (Worren et al.,
2002, p. 1228). As such, even if results can be produced in a laboratory, these results
do not necessarily translate into knowledge that is applicable in real-life settings and
useful for improving clinical practice. A pragmatic approach is used to determine
whether an intervention will be successful when implemented under normal
circumstances (Peat, 2001; Steen & Roberts, 2011). This study design adopted a
pragmatic approach to research.
Initially, in the planning stages of this study, consultation was completed with the
microbiology department of the St. George/Sutherland hospitals.

During this

consultation period, a variety of swab collection and testing techniques were
explored to determine the level of GBS and Lactobacilli counts in women’s vaginas.
One option that was explored was testing vaginal swabs with polymerase chain
reaction (PCR). PCR is a technique that amplifies the DNA sequences of a sample to
accurately identify the presence of specific organisms (Edwards et al., 2008). This
would be the most sensitive and accurate form of testing to investigate the micro
flora present in a woman’s vagina. The major drawback of this testing is the cost.
This method would also have required the researcher to collect every vaginal swab
from every participant. This would have been logistically very difficult to achieve. It
also would have increased the invasiveness of the study sampling methods, as
research indicates that women prefer to collect their own vaginal swabs (Mercer et
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al., 1995; Price et al., 2006). Despite these drawbacks, PCR still does remain a
possible option for future research studies.
After the microbiology consultation, and in light of the drawbacks, a more basic,
pragmatic approach was agreed upon. It was decided to utilise the study site’s
standard collection and testing techniques for GBS vaginal swabbing for the research
project. By doing so, the project was able to take advantage of the GBS vaginal
swab results routinely collected by all pregnant women at the study site at
approximately 36 weeks gestation.
The concerns that arose through using this approach revolved around the concepts of
consistency and specificity. The routine practice at the study site was that each
pregnant woman collected her own vaginal swab at a gestation of approximately
36 weeks. Self-collection is considered less invasive and has been shown to be
preferable to women (Mercer et al., 1995; Price et al., 2006). This called into
question the consistency of the swabbing collection techniques, since each woman
would collect her swab in a slightly different way. One manner in which this issue
was addressed was through consistent information distribution. In the antenatal
clinic, an informative brochure about GBS, including instructions on how to collect a
vaginal swab, was given to every woman when it was necessary for them to complete
the swab.

This information allowed for a degree of consistency in swabbing

techniques with the different participants.
In addition to consistent information distribution, each participant not only collected
her routine vaginal swab at 36 weeks but also self-collected her final vaginal swab
for the purposes of the study. This procedure allowed for a degree of internal
consistency because each individual participant collected both her own swabs.
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The second concern with the pragmatic approach was the specificity of the testing
techniques. The results of the standard vaginal swab testing at the microbiology labs
of the study site only specify the presence of a light, moderate or heavy growth of
GBS. They do not give numerical quantities. They also only report on the presence
of commensals, or normal vaginal flora, without specifying the identity of the flora.
This lack of specificity did not allow for the study to monitor any subtle changes in
the colonisation rates of vaginal GBS in the participants.
In defence of this choice, clinically, medical professionals are only concerned with
the presence or absence of GBS. They are not concerned with the specific quantities.
Therefore, in order to make the results of this study immediately relevant in the
clinical setting, which is the basis of a pragmatic approach, the study also only
focused on the presence or absence of GBS and the presence or absence of
commensals.
Although the pragmatic approach raised concerns regarding the consistency of swab
collection techniques among the participants and regarding the specificity of the GBS
results, it did utilise the standard processes undertaken at the study site. Since these
standard processes were used, it made the results immediately applicable, relevant
and understandable in the clinical setting to the clinicians who would be utilising
such information. As such, though the pragmatic approach limits the results of the
study, this approach can also be considered a strength of the research design. The
design flexed to work within the context of the clinical setting, instead of
manipulating the clinical setting to accommodate the study.

5.4 Strengths of the study
Despite the lack of positive results and the limitations of this research, strengths also
exist. The major strength of this study is its contribution to the growing body of

70

5. Discussion

knowledge supporting the safety of probiotic use in later pregnancy. The other
strengths are that it continues to justify the further investigation of the benefits of
probiotic use on vaginal GBS in pregnancy and it aids in the development of future
research designs. The following sections discuss these points in further detail.
5.4.1 Safety considerations
The lack of adverse events noted in this study with probiotic use in the third trimester
of uncomplicated pregnancies is a major strength of this study. The safety indicators
utilised in this study were adapted from the indicators used in two systematic reviews
conducted on the safety of probiotic use in pregnancy (Allen et al., 2010; Dugoua et
al., 2009).
The results showed that there were no differences between the intervention and
control groups with respect to the safety indicators investigated at and around the
time of birth. These safety indicators included birth weight, gestation at birth, mode
of delivery, pre-labour spontaneous rupture of membranes and infant concerns post
birth. The only significant result that was produced in the statistical analysis was that
women in the control group underwent assisted deliveries more often than women in
the probiotics group.

Assisted deliveries include instrumental deliveries and

emergency caesarean sections.

The significance remained even when the

participants were limited to nulliparous women, who research indicates have a
greater incidence of assisted delivery (Baskett et al., 2008). As mode of delivery was
one of the safety indicators, the higher probability of achieving a normal birth in the
probiotics group further supports the safety of the intervention.
The second set of data collected investigating the safety of the intervention was
through a follow-up telephone survey at approximately six months after the birth of
each of the participant’s infants. All 34 of the participants participated in the survey.
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Not one was lost to follow-up. The survey found that no differences existed between
the two groups relating to the overall health of the infants of the study participants at
six months of age. These findings further support the evidence that probiotic use in
later pregnancy produces no adverse events in healthy women experiencing
uncomplicated pregnancies.
5.4.2 Justification for further research
Another strength of this study is it suggests further research in this area may be
justified.

Commensals can be defined as normal vaginal micro flora, such as

Lactobacilli (Barrons & Tassone, 2008; Lagenaur et al., 2011b; Rose et al., 2012).
The significant presence of commensals in the vaginas of participants who had taken
daily probiotics positively reflects on the potential of probiotics to impact vaginal
GBS. The justification for this study was based on multiple, consistent research
findings which found that women with higher vaginal colonisations of Lactobacillus
are more likely to have no detectable vaginal GBS colonisations (Altoparlak et al.,
2004; Donders et al., 2000; Kubota et al., 2002; Takeyoshi et al., 2002; Whitney et
al., 2004). This finding from the current study supports the possibility that the
consumption of oral probiotics can result in the colonisation of the vagina with
Lactobacillus. This increases the potential then, in turn, to reduce or eradicate the
presence of GBS from the vagina. The door is still wide open for further research on
the use of probiotics to impact vaginal GBS.
5.4.3 Assistance in the development of study designs
This study’s significant finding of commensals in the vaginas of women who had
consumed probiotics, as discussed in the previous section, leads us on to the study’s
third strength. This strength is the information that this research provides in aiding
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the development of future study designs. Since this study had the unexpected finding
of showing an increase of vaginal commensals with probiotic use, future design
recommendations would include the presence of commensals as a research indicator.
They would also revolve around strategies for increasing the commensal
colonisations to a point where they can compete with and impact upon vaginal GBS.
These strategies, as discussed earlier in this chapter, include increasing the length of
the intervention, increasing the dose of the intervention and possibly changing the
species of Lactobacillus used.
This study was always intended to be a pilot project. It was developed to be the
initial research attempt for the purpose of testing the viability of this study design for
future research. As such, this project fulfilled its purpose. It was successful in
generating valuable information to help guide the actions of future researchers in
their design attempts.

5.5 Conclusion
In conclusion to the discussion chapter, the aim of this study was to complete a pilot
project to ascertain if the research design was appropriate to determine whether a
daily oral dose of probiotics can reduce the rate of vaginal group B streptococcal
(GBS) colonisation in pregnancy.

This research study has contributed valuable

information that has added to the growing body of knowledge around probiotic use in
pregnancy.

It did generate multiple avenues of exploration for future research.

These avenues include research designs which incorporate longer intervention times,
higher probiotic doses and different probiotic strains. These future designs may also
incorporate larger sample sizes, different sampling techniques and different swab
testing techniques. Many possibilities for future research are apparent from this pilot
project.
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In addition, a major strength of the current study was that its findings have provided
further support for the safety of probiotic use in later pregnancy by healthy women
experiencing normal pregnancies. All the findings of this study coincide to declare
that the opportunity still remains for future research to uncover the preventative
potential of probiotics for vaginal GBS in pregnancy.

74

6. Conclusion

6 CONCLUSION
6.1 Introduction
The final chapter of this thesis reiterates the findings of the study in light of the
original aim of the study: to complete a pilot project to determine if the research
design of this study was appropriate to determine if a daily oral dose of probiotics
can reduce the rate of vaginal group B streptococcal (GBS) colonisation in
pregnancy. This chapter also reflects on the study’s success at achieving this aim. It
summarises the potential reasons for the lack of a reduction in vaginal GBS with oral
probiotic use that was seen in this study. This chapter also presents the implications
this study has for future research projects as well as for clinical practice.

6.2 Summary of findings
The main finding of the study was that there was no significant difference in vaginal
GBS colonisation rates in women who had consumed a daily oral dose of probiotics
as compared to women who had not. This lack of significant difference remained
even when a subgroup analysis was performed including only those participants who
had consumed 14 days or more of probiotics. One unexpected finding from the
subgroup analysis was that significantly more women who had taken probiotics had
commensals colonising their vaginas (p=0.048). Commensals are normal vaginal
flora, such as Lactobacilli (Barrons & Tassone, 2008; Lagenaur et al., 2011b; Rose et
al., 2012).
Another significant finding was that there were no differences between the probiotics
group and the standard care group with respect to the safety indicators investigated.
This lack of difference in the safety indicators was present throughout all stages of
the research trajectory, including the antenatal period, labour and birth, the postnatal
period and six months post birth.
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6.3 Achievement of study aims
The hypothesis of the study asked the question: if Lactobacillus colonisation rates
can be increased in pregnant women’s vaginas, could this result in a decrease in
group B streptococcal (GBS) colonisation rates? The aim of the study was to pilot
the appropriateness of this research design to determine whether a daily oral dose of
probiotics can reduce the rate of vaginal group B streptococcal (GBS) colonisation in
pregnant women.
As stated in section 6.2, ‘Summary of findings’, no significant difference was found
in vaginal GBS colonisation between the participants who consumed daily oral doses
of probiotics and those who were in the control group. Even though there was a lack
of positive results, this study still attained its aim. The study was investigating the
appropriateness of this specific research design in addressing the question raised by
the hypothesis. The investigation has shown that this is not an effective study design
to trial the impact of oral probiotics on vaginal GBS colonisation.
However, this research, through its design, has laid foundational groundwork for
future research.

The main drawback of the study design was the length of

intervention. Only seven of the 21 women recruited to the probiotics group were
successful in completing the entire three-week intervention. This limitation was due
to the uncontrollable nature of labour and birth and the late gestation at which
women were recruited. This is one obvious area which has the opportunity to be
addressed with future research and already the findings have been disseminated
through national and international conferences (Appendix I). Other areas that may
have contributed to the lack of positive results were a potentially inadequate
probiotic dosage and a potentially incorrect probiotic strain.
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6.4 Recommendations for future research
The finding of significantly more women who had consumed 14 or more days of
probiotics with vaginal commensal colonisation when compared to the control group
continues to support the potential of oral probiotics to impact the vaginal micro
environment.

Future research possibilities exist investigating the impact of

probiotics with longer intervention times, higher doses of probiotics and different
strains of probiotics. Future research should plan to recruit women at an earlier
gestation in their pregnancies. Future designs may also incorporate larger sample
sizes, different sampling techniques and different swab testing techniques. Many
possibilities for future research are apparent from this pilot project.

6.5 Implications for clinical practice
The major implication for clinical practice that has arisen through this research is it
has provided further evidence to support the lack of adverse events with probiotic use
in later pregnancy by healthy women experiencing normal pregnancies. Even though
no significant positive results were obtained through this specific research study, the
potential of probiotic use in pregnancy remains. This project continues to reinforce
the use of probiotics by pregnant women if they choose to pursue this avenue of
health. Due to the results of this study, clinicians can support women in these
choices with reduced concerns about the safety of probiotic use in later pregnancy.

6.6 Final remarks
Although this pilot project did not succeed in providing evidence that oral probiotic
usage in pregnancy can impact vaginal GBS colonisation, it did achieve its piloted
aim, which was to determine the validity of the study design used. This aim was
achieved in this thesis by highlighting the limitations in the study design, which will
aid in guiding the development of future research designs. The results of this study
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did not close the door on the potential use of probiotics to impact vaginal GBS, but
rather opened the opportunity for future research in this field. The opportunity still
remains for research to uncover the preventative potential of probiotics for vaginal
GBS in pregnancy.
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8.1 Appendix A: Antenatal promotional poster

The hospital is doing research to try and answer this question:

Can Probiotics Improve the Bacteria in your Vagina?
 20% of pregnant Australian women have a bacteria in
their vaginas called Group B Streptococcus (GBS)
 GBS does not hurt the women but babies who are
infected during labour and birth can become seriously ill
 We are seeking to find out if a daily oral dose of
probiotics can prevent this infection
 You can be involved if you are over 18 yrs old, are having
a normal healthy pregnancy, and have been found to
have GBS in your vagina at 36 weeks pregnant
 If you are interested in participating in this research, then
please talk to your doctor or midwife
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8.2 Appendix B: Participant Information Sheet

PARTICIPATION INFORMATION SHEET FOR PREGNANT WOMEN
Title: Study Investigating the Impact of Oral Probiotic Use on Vaginal Group B
Streptococcal Rates in Pregnant Women: A Pilot Randomised Controlled Study
Purpose of the Research
This is an invitation to participate in a study conducted by a Master’s Research
Student (Paula Olsen), under the supervision of experienced researchers, at the
University of Wollongong. The purpose of this research is to determine if taking a
certain strain of oral probiotics can decrease the number of pregnant women with a
bacterial colonisation called Group B Streptococcus (GBS) in their vaginas.
Probiotics are live micro-organisms that pass on a health benefit to the person taking
them. GBS infections may cause serious illness in some newborn babies. If this
study is successful it will show that there may be a way to prevent GBS colonisation
of the vagina. It could then become the basis of a larger research study in order to
prove the effectiveness of probiotics in treating GBS vaginal colonisation.
Investigators
Paula Olsen
Dr Moira Williamson
Professor
Don
Iverson
Dr Chris Georgiou
Registered Midwife/Masters Student
Health & Behavioural Sciences
Pro ViceChancellor (Health)
IHMRI/Grad School Medicine
(02) 4221- 3381
(02)
42214677
(02) 4222-5000
Pgc589@uow.edu.au
moiraw@uow.edu.au
daynah@uow.edu.au
georgiou@uow.edu.au

Demands on Participants
If you decide to be involved in the research you will be randomly chosen to either
continue with your standard antenatal care or continue with your standard care plus
to take the oral probiotics Lactobacillus Rhamnosus GR-1 and Lactobacillus Reuteri
RC-14 daily for three weeks from about the thirty-sixth week of your pregnancy.
You will also be required to participate in a telephone survey when your baby is 6
months old. This survey should take about 10 minutes of your time.
Possible Risks, Inconveniences and Discomforts
If you are randomly chosen to be in the probiotics group, you will have the
inconvenience of taking oral probiotics daily for three weeks. The probiotics will be
provided to you free of charge. All participants will be required to collect an
additional vaginal swab at about 39 weeks pregnant.
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There is a small chance that probiotics can cause some infections; these infections
generally only occur in people who have underlying chronic illnesses. There is no
expected risk to your baby. Research studies have been done testing probiotics in
pregnancy. Most of these studies have been different from this current study because
they have investigated whether taking probiotics in pregnancy can reduce the
chances of infants developing allergies. None of these studies have reported any
adverse events from the probiotics. The specific strains of probiotics to be used in
this study have not previously been tested in pregnancy. They have been tested in
healthy women who are not pregnant and have resulted in no adverse events. These
strains are theoretically safe for use in pregnancy but their absolute safety has not yet
been proven through research studies. The follow-up telephone survey will help to
prove the safety of these probiotics by providing the researchers with the chance to
ask questions about the well-being of yourself and your baby after being involved in
the study.
It is current hospital policy that all women found to have GBS in their vaginas
receive intravenous antibiotics in labour. This is an initial study to test if probiotics
have any impact on GBS in vaginas. As a result, all women participating in the
research will still be encouraged to have intravenous antibiotics in labour in
accordance with current hospital policy. Any results from this study will not alter the
treatment you will receive during your pregnancy or your labour.
Your involvement is completely voluntary and you are free to withdraw your
participation and your information at any time. If you choose not to participate or
choose to withdraw from participation this will not impact the care you receive
during your pregnancy at the Sutherland Hospital. All information gathered
throughout the research will be kept strictly confidential.
Funding and Benefits of the Research
The funding for this research is being provided by the Edith Cavell Trust. If
probiotics are found to reduce the rate of GBS in pregnancy this will give women a
possible strategy to prevent GBS vaginal colonisation. It also may decrease the
number of women receiving intravenous antibiotics in labour as a result reducing the
number of newborns exposed to this bacterium. This study will provide preliminary
evidence on which to base a larger, more definitive research study.
Ethics Review and Complaints
This study has been reviewed by the Human Research Ethics Committee of the
University of Wollongong. If you have any concerns or complaints regarding the
way this research has been conducted, you can contact the University of
Wollongong’s ethics officer on (02) 4221-4457.
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8.3 Appendix C: Diagram of research design
Women at 33 weeks gestation attending the antenatal clinic at Sutherland Hospital all receive a research study brochure and
participant information sheet

Women at 36 weeks gestation routinely self-collect lower vaginal swab. The swab is returned to the doctor or midwife at the
clinic.

GBS +ve

GBS -ve

Researcher telephone contact to invite women to
participate .

Accept

No further contact by researcher.

decline
No further contact by researcher.

Interested women approached at next antenatal visit by researcher – informed consent obtained – randomised into control or
intervention group.

Intervention

Control

Standard care plus daily oral dose of probiotics for 3 weeks.

Standard care.

At 39 weeks both groups repeat lower vaginal swab.

Data Analysis after birth
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8.4 Appendix D: Participant data collection sheet

Probiotics and GBS Research Form
Coding #________________________________________
Date of entry____________________________________
MRN___________________________________________
EDC____________________________________________
Gestation on entry_________________________________
Parity___________________________________________
BMI_____________________________________________
Ethnicity________________________________________
Age_____________________________________________
Past hx of GBS_____________________________________
RESEARCH GROUP

(Please Circle)

 STANDARD CARE PLUS PROBIOTICS

 STANDARD CARE
Did you take any antibiotics during the trial period? For how long?
__________________________________________________________
Were you able to take the probiotics every day? How many days
were missed?
__________________________________________________________
Did you have any adverse side effects to the probiotics? Provide
details.
__________________________________________________________
__________________________________________________________
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Pregnancy & Birth
Complications in pregnancy?
__________________________________________________________
What kind of birth and why?

Given antibiotics while in labour (why or why not)?

What was the baby’s birth weight?

Final Swab Result
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8.5 Appendix E: Consent form

CONSENT FORM FOR PREGNANT WOMEN
The impact of oral probiotic use on vaginal Group B Streptococcal rates in
pregnant women: a pilot randomised controlled study
Researcher: Paula Olsen
I have been given information about “The impact of oral probiotic use on the vaginal
Group B Streptococcal rates in pregnant women” and discussed the research project
with the researcher. I understand that Paula Olsen is conducting this research as part
of a Master of Midwifery (Research) degree and is being supervised by Dr Moira
Williamson, Professor Don Iverson and Dr Chris Georgiou from the University of
Wollongong.
I have been advised of the potential risks and burdens associated with this research,
which includes the possible inconvenience of taking a daily dose of oral probiotics
for three weeks. It has been explained to me that there is an extremely low risk of
developing some form of infection from the probiotics and these infections generally
only occur in people with underlying chronic illness. There is no anticipated risk to
myself or my developing infant. I have had the opportunity to contact Paula Olsen
with any questions I may have about the research and my participation.
I understand that my participation in this research is voluntary, I am free to refuse to
participate and I am free to withdraw from the research at any time. My refusal to
participate or withdraw consent will not affect the care I receive during my pregnancy
at Sutherland Hospital in any way.
If I have any enquiries about the research, I can contact Paula Olsen on
and Dr Chris Georgiou on (02) 4222-5000 or if I have any concerns or complaints
regarding the way the research is or has been conducted, I can contact the Ethics
Officer, Human Research Ethics Committee, Office of Research, University of
Wollongong on 4221 4457.
By signing below I am indicating my consent to:
• being randomly chosen to either continue with the standard antenatal care or to
receive standard care plus taking orally the probiotic strains Lactobacillus
Rhamnosus GR-1 and Lactobacillus Reuteri RC-14 for three weeks from
approximately 36 weeks gestation.
I understand that the data collected from my participation will be used for a thesis,
journal articles, conference presentations and a larger research study. I consent for it
to be used in these manners. I understand that my identity will not be disclosed
through any of these uses.
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Signed

Date

.......................................................................
Name (please print)

......./....../......

.......................................................................
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8.6 Appendix F: Information brochure
Did you know…
 The Sutherland hospital is doing research, in collaboration with
IHMRI, into whether oral probiotics can prevent Group B Streptococcus
from colonising pregnant women’s vaginas
 If your vaginal swab result at 36 weeks shows that you have Group B
Streptococcus you may receive a phone call from a researcher to see if
you would be interested in being involved in this study.
 If you receive a phone call and do NOT want to be involved just tell
the researcher. You will not be contacted again and it will not impact
the care you receive at the clinic in any way.
 If you would like to be involved, the researcher will meet with you
the next time you are at the hospital. You will be able to ask the
researcher any questions you may have at this time.
 Women who would like to be involved will be randomly chosen either
to continue with the usual antenatal care or to continue with the usual
antenatal care & receive an oral dose of probiotics daily for three
weeks. All women who are involved will then recollect their own
vaginal swab at 39 weeks into the pregnancy.

101

Appendices

8.7 Appendix g: Follow-up telephone survey at six months
Follow-up Telephone Survey at Six Months
Preamble
Hello, may I speak to _____________ please? It’s Paula Olsen calling. You were
involved in a research project at the Sutherland Hospital during your pregnancy. I
am just calling to ask some questions about you and your baby’s health over the past
six months. These questions should take about 10 minutes to answer. Is this a
convenient time or would another time be better for you?

Background Information
How is the baby fed?




Breast
Formula
Combination

How long was the baby exclusively breastfed for?

Are there any smokers in the house?

Do you keep any pets in the house?

Does the baby go to child care?

Do you have any family history of allergies, asthma or eczema?

Infant

Did the baby have any health concerns at birth?

How many times have you taken the baby to the GP?
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Has the baby ever been hospitalised?

Have you given any medications to your baby?

Has the baby had any signs of allergies? Eczema? Asthma? Allergic Rhinitis?
How would you describe your baby’s health?




Very healthy
Occasionally unwell
Nearly always unwell

Any other health concerns that you would like to mention regarding your baby?
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8.8 Appendix H: Consort Flow Diagram
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8.9 Appendix I: Successful Conference Abstracts
1.

Asia Pacific midwives conference 2009, Hyderabad, India—oral
presentation

Developing Natural Ways for Preventing Group B Streptococcal Vaginal Infections
in Pregnancy

Group B Streptococcus (GBS) is an organism that has been recognized in the
developed world since the 1970s as the leading cause of neonatal sepsis. GBS
infection is vertically transmitted from an asymptomatic mother to her infant during
labour and birth. Considering the serious consequences of neonatal GBS infection,
strategies for prevention have so far focused on administration of antibiotics to
women in last week of pregnancy or administering antibiotics during labour.

The disadvantages of these strategies are the development of antibiotic resistance in
GBS and non-GBS pathogens, the disruption of the colonization of the neonates’ gut
with the appropriate flora, the risk of maternal anaphylaxis, the deficit in maternal
knowledge regarding GBS and the medicalization of birth.

It is commonly

understood that administering intravenous antibiotics in labour to prevent neonatal
GBS is only an intermediate solution until better solutions are developed.

In response to these facts and the seriousness of GBS infection, it becomes apparent
that future research is necessary to determine natural ways of increasing
Lactobacillus colonisations in women’s vaginas in order to decrease GBS
colonisation rates and to protect their infants from exposure to GBS infections. This
presentation will discuss natural ways in which GBS vaginal infections can be
prevented.
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2. Australian College of Midwives National Conference 2011, Sydney,
Australia— Poster presentation
The impact of oral probiotic use on vaginal Group B Streptococcal colonisation rates
in pregnant women: A pilot randomised controlled study

Background
Group B Streptococcus (GBS) is the leading cause of bacterial infections in the
neonate in the developed world. This bacterium is passed from a woman’s vagina to
her new-born during the process of labour and birth, potentially causing pneumonia,
septicaemia and meningitis in the infant. In order to prevent neonatal GBS infections
most hospitals have protocols in place that identify pregnant women at risk of
infecting their new-borns and give these women intravenous antibiotics in labour to
inhibit the transmission. The disadvantages of intravenous antibiotics in labour are
the development of antibiotic resistance in GBS and non-GBS pathogens, the
inhibition of the colonisation of the new-born’s gut with the appropriate flora and the
medicalisation of childbirth.
It has been shown that women with higher colonisation of vaginal Lactobacillus are
more likely to have no detectable vaginal GBS. This raises the hypothesis: Would
increasing the colonisation rates of Lactobacillus in pregnant women’s vaginas result
in a decrease in GBS colonisation rates? A pilot randomised controlled trial is
proposed to determine if oral probiotics may be a strategy for decreasing GBS
vaginal colonisation rates by increasing vaginal Lactobacillus rates.
Methods
A sample of thirty GBS positive pregnant women will be recruited. The GBS status
of these women will be determined by the routine lower vaginal swabs that are selfcollected by all women in the antenatal clinic at the proposed hospital site at thirtysix weeks gestation. These women will be randomised into control and intervention
groups. The control group will continue with standard care; the intervention group
will receive standard care and take a daily dose of oral probiotics for three weeks.
After three weeks both groups will repeat the self-collection of a lower vaginal swab.
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It is anticipated that the data collection phase will take approximately three months.
A telephone survey will be performed at six months postpartum in order to verify the
safety of the intervention.
Expected Outcomes
It is expected that a significant number of women in the intervention group will be
GBS negative after three weeks of oral probiotics when compared with the control.
A positive outcome would then become the basis of a larger randomised control trial.
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3. Breathing New Life into Maternity Care conference 2012, Melbourne,
Australia—poster presentation
The impact of oral probiotic use on vaginal Group B Streptococcal colonisation rates
in pregnant women: A pilot randomised controlled study
Background
Group B Streptococcus (GBS) is the leading cause of bacterial infections in the
neonate in the developed world. This bacterium is passed from a woman’s vagina to
her new-born during the process of labour and birth, potentially causing pneumonia,
septicaemia and meningitis in the infant. In order to prevent neonatal GBS infections
most hospitals have protocols in place that identify pregnant women at risk of
infecting their new-borns and give these women intravenous antibiotics in labour to
inhibit the transmission. The disadvantages of intravenous antibiotics in labour are
the development of antibiotic resistance in GBS and non-GBS pathogens, the
inhibition of the colonisation of the new-born’s gut with the appropriate flora and the
medicalisation of childbirth.
It has been shown that women with higher colonisation of vaginal Lactobacillus are
more likely to have no detectable vaginal GBS. This raises the hypothesis: Would
increasing the colonisation rates of Lactobacillus in pregnant women’s vaginas result
in a decrease in GBS colonisation rates? A pilot randomised controlled trial is
proposed to determine if oral probiotics may be a strategy for decreasing GBS
vaginal colonisation rates by increasing vaginal Lactobacillus rates.
Methods
Thirty-five women found to have GBS colonisation in their vaginas at 36 weeks
gestation were recruited into the study. These women were randomised into control
and intervention groups. The control group continued with standard care and the
intervention group continued with standard care in addition to receiving a daily oral
dose of probiotics. Three weeks after recruitment or while in labour, depending on
which occurred first, a lower vaginal swab was collected. These swabs were sent to
pathology to be tested for the presence of GBS. Six months post the birth of their
infants, the participants then engaged in a follow-up telephone survey to determine
the safety of the intervention.
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Outcomes
The data analysis phase of the project is ensuing at the moment. The results of these
findings will be presented. These results will include an emphasis on the safety of
probiotic use in pregnancy, an area of great current interest in obstetrics.
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4. International Confederation of Midwives conference 2014, Prague,
Czechoslovakia—oral presentation
The impact of oral probiotic use on vaginal Group B Streptococcal colonisation rates
in pregnant women: A pilot randomised controlled trial

Aim
The main hypothetical question was: Can a daily oral dose of probiotics reduce the
rate of vaginal Group B Streptococcal (GBS) colonisation in pregnancy? The aim
was to test the viability of this specific study design to address the hypothesis.

Methodology
A pilot randomised controlled trial was performed which recruited 34 GBS positive
women at approximately 36 weeks pregnant.

The participants were randomly

allocated to the control group, which continued with standard antenatal care, or to the
intervention group, which continued with standard antenatal care and received a
daily oral dose of probiotics for 3 weeks or until the birth of their infant. A lower
vaginal swab, to determine the presence of GBS, was collected 3 weeks post consent
or when a participant was in labour.

Results
No significant difference was found in vaginal GBS between the control and
intervention groups. Only 7 of 21 in the intervention group completed the entire 21
days of probiotics. A sub-group analysis, including only those who had completed
14 days or more of probiotics, also showed no significant difference in vaginal GBS
when compared to the control. It did show significantly more vaginal commensals in
the probiotics group.

Discussion
There are 4 possible reasons for the lack of significant results:


The length of the intervention was too short.



The dosage of the probiotics was too low.



The wrong strain of probiotics was used.



Oral probiotics are ineffective at impacting vaginal GBS.
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Implications
The significant increase of vaginal commensals (normal vaginal flora, including
Lactobacilli) in women who had completed 14 days or more of probiotics continues
to support the potential of probiotics to impact GBS in pregnancy. This pilot project
supports the safety of probiotic use in later pregnancy. Many possibilities remain for
future research to further investigate the use of probiotics to impact vaginal GBS.
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